

# DUKE UNIVERSITY MEDICAL CENTER

## CURRICULUM VITAE

Date Prepared: May 11, 2022

### Barbara Dudley Alexander, M.D., M.H.S.

**Primary academic appointment:** Medicine/Infectious Diseases  
**Secondary appointment:** Pathology / Section Head Clinical Mycology Laboratory  
**Present academic rank and title:** Professor of Medicine (with tenure)  
Professor of Pathology  
**Date and rank of first Duke faculty appointment:** 7/1/99, Associate in Medicine  
**Medical licensure and date:** NC, 5/22/1999  
**Specialty certification and dates:** Internal Medicine, 1/1/98  
Infectious Diseases, 11/3/99, 2/1/10  
Medical Microbiology, 9/16/99

<b>Education:</b>	<b>Institution</b>	<b>Date</b>	<b>Degree</b>
High School:	Williams Township	1977-1981	HS Diploma
College:	Southeastern Community College	1981-1983	College Transfer
	UNC at Wilmington	1983-1985	B.A., Biology
Graduate/Professional School:			
	Duke University	1985-1986	Medical Technology
	East Carolina University	1989-1993	M.D.
	Duke University	2003-2006	Masters in Health Science

**Scholarly societies:** Alpha Omega Alpha

#### Professional training and academic career:

Duke University Medical Center:

1993 - 1994	Internship, Internal Medicine
1994 - 1996	Residency, Internal Medicine
1996 - 1998	Fellowship, Infectious Diseases
1998 - 1999	Fellowship, Medical Microbiology

Massachusetts General Hospital:

February 1999	Visiting Fellowship, Transplant Infectious Diseases
---------------	---

Duke University:

1999-2002	Associate in Medicine
2002-2007	Assistant Professor of Medicine
2007-2010	Associate Professor of Medicine and Pathology
2011-2014	Associate Professor of Medicine (with Tenure) Associate Professor of Pathology
2014-present	Professor of Medicine and Pathology (with Tenure)

**Refereed Publications – Articles in Print**

1. **Alexander BD**, Perfect JP. Antifungal resistance trends towards the year 2000: implications for therapy and new approaches. *Drugs* 1997;54(5):657-78.
2. Palmer SM, **Alexander BD**, Sanders LL, Edwards LJ, Reller LB, Davis RD, Tapson VF. Significance of bloodstream infection after lung transplantation: analysis in 176 consecutive patients. *Transplantation* 2000;69(11):2360-2366.
3. Smith SR, Butterly DW, **Alexander BD**, Greenburg A. Viral infections after renal transplantation. *Am J Kidney Dis* 2001;37(4):659-676.
4. **Alexander BD**, Tapson VF. Infectious complications of lung transplantation. *Transpl Infect Dis* 2001;3:128-137.
5. Dictar MO, Maiolo E, **Alexander BD**, Jacob N, Veron MT. Mycoses in the transplanted patient. *Med Mycology* 2001;38(Suppl 1):251-258.
6. **Alexander BD**, Stout JE, Reller LB, Hamilton CD. Impact of a high prevalence of Mycobacterium Other Than Tuberculosis in a region with a low incidence of tuberculosis. *Infect Control Hosp Epidemiol* 2001;22(11):715-717.
7. **Alexander BD**. Diagnosis of fungal infection: new technologies for the mycology laboratory. *Transpl Infect Dis* 2002;4(S3):32-37.
8. Streyjewski ME, LiPuma JJ, Messier RH, Reller LB, **Alexander BD**. Sepsis, multiple organ failure, and death due to *Pandoraea pnomenusa* after lung transplantation. *J Clin Microbiol* 2003;41(5):2255-2257.
9. Singh N, Avery RK, Munoz P, Pruett TL, **Alexander BD**, Jacobs R, Tollemar JG, Dominguez EA, Yu CM, Paterson DL, Husain S, Kusne S, Linden P. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. *Clin Infect Dis* 2003;36:46-52.
10. Martagon-Villamil J, Shreshta N, Sholtis M, Isada CM, Hall GS, Bryne T, **Alexander Lodge B**, Reller LB, Procop GW. Identification of *Histoplasma capsulatum* from culture extracts and clinical specimens by lightcycler PCR. *J Clin Microbiol* 2003; 41:1295-1298.
11. Husain S, **Alexander BD**, Munoz P, Avery RK, Houston S, Pruett T, Jacobs R, Dominguez EA, Tollemar JG, Yu CM, Baumgarten K, Wagener MM, Linden P, Kusne S, Singh N. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-*Aspergillus* mycelial fungi. *Clin Infect Dis* 2003;37:221-229
12. Friedman ND, Peterson NB, Sumner WT, **Alexander BD**. Spontaneous dermal abscesses and ulcers due to *Serratia marcescens*. *J Am Acad Dermatol* 2003; 49(S2): S193-194.
13. Zaas AK, Boyce M, Schell W, **Alexander Lodge B**, Miller JL, Perfect JR. Risk of fungemia due to *Rhodotorula* and antifungal susceptibility testing of *Rhodotorula* isolates. *J Clin Microbiol* 2003;41(11):5233-5235.
14. Woods CW, Bressler AM, LiPuma JJ, **Alexander BD**, Clements DA, Weber DJ, Moore CM, Reller LB, Kaye KS. Virulence associated with outbreak-related strains of *Burkholderia cepacia* complex among a cohort of patients with bacteremia. *Clin Infect Dis* 2004;38:1243-50.

15. **Alexander Lodge B**, Ashley ED, Steele MP, Perfect JR. *Aspergillus fumigatus* empyema, arthritis, and calcaneal osteomyelitis in a lung transplant patient successfully treated with posaconazole. *J Clin Microbiol* 2004;42(3):1376-1378.
16. Paya C, Humar A, Dominguez E, Washburn WK, **Alexander B**, Blumberg E, Freeman R, Heaton N, Macey K, Tansley R, Pescovitz MD. Efficacy and safety of once-daily oral valganciclovir vs oral ganciclovir three times daily for the prevention of cytomegalovirus disease in solid organ transplant recipients. *Am J of Transplantation* 2004;4(4):611-620.
17. Boivin G, Goyette N, Gilbert C, Roberts N, Macey K, Paya C, Pescovitz M, Humar A, Dominguez E, Washburn K, Blumberg E, **Alexander B**, Freeman R, Heaton N, Covington E. Absence of CMV resistance mutations following valganciclovir prophylaxis in a prospective multicenter study in solid organ transplant recipients. *J Infect Dis* 2004;189:1615-1618.
18. Humar A, Paya C, Pescovitz M, Dominguez E, Washburn K, Blumberg E, **Alexander B**, Freeman R, Heaton N, Mueller B. Clinical utility of CMV viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients. *Am J Transplantation* 2004;4:189:1614-1618.
19. Freeman R, Macey K, Paya C, Pescovitz M, Humar A, Dominguez E, Washburn K, Blumberg E, **Alexander B**, Heaton N, and the Valganciclovir Solid Organ Transplant Study Group. Risk factors for cytomegalovirus disease: results from a multicenter randomized trial of valganciclovir. *Transplantation* 2004;78(12):1765-1773.
20. Wiltshire H, Hirankarn S, Farrell C; Paya C, Pescovitz M, Humar A, Dominguez E, Washburn K, Blumberg E, **Alexander B**, Freeman R, Heaton N, and the Valganciclovir Solid Organ Transplant Study Group. Pharmacokinetic profile of oral ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. *Clin Pharmacokinetics* 2005;44(5):495-507.
21. Husain S, Muñoz P, Forrest G, **Alexander B**, Somani J, Brennan K, Wagener M, Singh N. Infections due to *Scedosporium apiospermum* and *Scedosporium prolificans* in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. *Clin Infect Dis* 2005;40:89-99.
22. Blankenship J, Singh N, **Alexander B**, Heitman J. *Cryptococcus neoformans* isolates from transplant recipients are not selected for resistance to calcineurin inhibitors by current immunosuppressive regimens. *J Clin Microbiol* 2005;43(1):1170-1174.
23. **Alexander BD** and Wingard JR. Study of renal safety in amphotericin B lipid complex (ABLC)-treated patients: analysis of the CLEAR<sup>®</sup> database. *Clin Infect Dis* 2005;40(6):S415-S421.
24. Singh N, Lortholary O, **Alexander BD**, Gupta KL, John GT, Pursell K, Munoz P, Klintmalm GB, Stosor V, Del Busto R, Limaye AP, Somani J, Lyon M, Houston S, House AA, Pruett TL, Orloff S, Humar A, Dowdy LA, Garcia-Diaz J, Kalil AC, Fisher RA, Husain S, and the Cryptococcus Transplant Study Group. An “immune reconstitution syndrome”-like entity associated with *Cryptococcus neoformans* infection in organ transplant recipients. *Clin Infect Dis* 2005;40:1756-1761.

25. Wilson M, Joyce M, Hall L, Reller L, Roberts G, Hall G, **Alexander B**, Procop G. Multicenter evaluation of a *Candida albicans* PNA FISH Probe for blood cultures that grow yeasts. *J Clin Microbiol* 2005;43(6):2909-12.
26. Ostrosky-Zeichner L, **Alexander BD**, Kett D, Vazquez J, Pappas P, Saeki F, Ketchum PA, Wingard JR, Schiff RA, Tamura H, Finkelman MA, Rex JH. Multicenter clinical evaluation of the (1->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. *Clin Infect Dis* 2005;41(5):654-659.
27. Zaas AK and **Alexander BD**. Echinocandins: role in antifungal therapy. *Expert Opinion in Pharmacotherapy* 2005;6(10):1657-68.
28. **Alexander BD**, Schell WA, Miller JA, Long GD, Perfect JR. *Candida glabrata* fungemia in transplant patients receiving voriconazole. *Transplantation* 2005;80(6):868-71.
29. Singh N, Lortholary O, **Alexander BD**, Gupta KL, John GT, Pursell K, Munoz P, Klintmalm GB, Stosor V, Del Busto R, Limaye AP, Somani J, Lyon M, Houston S, House AA, Pruett TL, Orloff S, Humar A, Dowdy L, Garcia-Diaz J, Fisher RA, Husain S and the Cryptococcal Collaborative Transplant Study Group. Allograft loss in renal transplant recipients with *Cryptococcus neoformans* associated immune reconstitution syndrome. *Transplantation* 2005;80(8):1031-1133.
30. Singh N, Lortholary O, **Alexander BD**, Gupta KL, John GT, Pursell KJ, Munoz P, Klintmalm GB, Stosor V, Del Busto R, Limaye AP, Somani J, Lyon M, Houston S, House A, Pruett TL, Orloff S, Humar AA, Dowdy LA, Garcia-Diaz J, Kalil AC, Fisher RA, Husain S. Antifungal management practices and evolution of infection in organ transplant recipients with *Cryptococcus neoformans* infection. *Transplantation* 2005;80(8):1033-1039.
31. Costa SF and **Alexander BD**. Non-*Aspergillus* fungal pneumonia in transplant recipients. *Clinics in Chest Medicine* 2005;26(4):675-90.
32. Upton A, Gugel A, Leisenring W, Limaye A, **Alexander B**, Hayden R, Marr K. Reproducibility of low galactomannan enzyme immunoassay index values tested in multiple laboratories. *J Clin Microbiol* 2005;43(9):4796-800.
33. Zaas AK and **Alexander BD**. Galactomannan and advances in fungal diagnostics. *Current Opinion in Organ Transplantation* 2005;10(4):307-311.
34. Wiltshire H, Paya C, Pescovitz M, Humar A, Dominguez E, Washburn K, Blumberg E, **Alexander B**, Freeman R, Heaton N, Zuideveld, K, and the Valganciclovir Solid Organ Transplant Study Group. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. *Transplantation* 2005;79(11):1477-83.
35. **Alexander BD**, Dodds Ashley ES, Addison RM, Alspaugh JA, Chao NJ, Perfect JR. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. *Trans Infect Dis* 2006;8:13-20.
36. **Alexander BD**, Dodds Ashley E, Reller LB, Reed SD. Cost savings with implementation of PNA FISH testing for identification of *Candida albicans* in blood cultures. *Diagn Microbiol Infect Dis* 2006;54(4):277-82.

37. **Alexander BD** and Pfaller MA. Contemporary tools for the diagnosis of invasive mycoses. *Clin Infect Dis* 2006;43:S15-27.
38. Anaissie EJ, Segal BH, Graybill JR, Arndt C, Perfect JR, Kleinberg M, Pappas P, Benjamin D, Rubin R, Aberg JA, Adderson EE, Adler-Shohet FC, Akan H, Akova M, Almyroudis NG, **Alexander BD**, et al. Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. *Clin Infect Dis* 2006;43(8):1031-9.
39. Zaas A, Ashley ED, **Alexander B**, Johnson M, Perfect JR. Caspofungin for invasive candidiasis at a tertiary care medical center. *Am J Med* 2006;119(11):993.
40. Cohen-Wolkowicz M, Smith PB, Mangum B, Steinbach WJ, **Alexander BD**, Cotton CM, Clark RH, Walsh TJ, Benjamin DK. Diagnosis of neonatal *Candida* meningitis: significance of cerebrospinal fluid parameters and blood cultures. *J Perinatology* 2007;27:97-100.
41. Hanson KE and **Alexander BD**. Strategies for the prevention of infection after solid organ transplantation. *Expert Reviews of Anti-Infective Therapy* 2006;4(5):837-852.
42. Ostrosky-Zeichner L, Sable C, Sobel J, **Alexander B**, Donowitz G, Kan V, Kauffman C, Kett D, Larsen R, Morrison V, Nucci M, Pappas P, Bradley M, Major S, Zimmer L, Wallace D, Rex J. Multicenter retrospective development and validation of a clinical prediction rule for invasive candidiasis in the intensive care setting. *Eur J Clin Microbiol Infect Dis* 2007;26:271-276
43. Hanson KE, Reller LB, Kurtzberg J, Horwitz M, Long G, **Alexander BD**. Comparison of the Roche CMV UL54 analyte specific reagent and Qiagen RealArt™ CMV LC PCR reagent, with Digene Hybrid Capture® System CMV DNA Test (version 2.0) using AcroMetrix OptiQuant™ CMV DNA quantification panels and specimens from allogeneic stem cell transplant recipients. *J Clin Microbiol* 2007;45:1972-1973.
44. Weinberg JB, **Alexander BD**, Majure JM, Williams LW, Kim JY, Vandamme P, LiPuma JJ. *Burkholderia glumae* infection in an infant with chronic granulomatous disease. *J Clin Microbiol.* 2007;45:662-665.
45. Singh N, **Alexander BD**, Lortholary O, Gupta KL, John GT, del Busto R, Klintmalm GB, Somani J, Lyon M, Pursell K, Stosor V, Munoz P, Limaye AP, Kalil AC, Pruett TL, Garcia-Diaz J, Humar A, Houston S, House AA, Wray D, Orloff S, Dowdy LA, Fisher RA, Heitman J, Wagener MM, Husain S, and the Cryptococcal Collaborative Transplant Study Group. *Cryptococcus neoformans* in organ transplant recipients: impact of calcineurin-inhibitor agents of mortality. *J Infect Dis.* 2007;195:756-64.
46. Steinbach WJ, Addison RM, McLaughlin L, Gerrald Q, Martin PL, Driscoll T, Bentsen C, Perfect JP, **Alexander BD**. Prospective *Aspergillus* galactomannan antigen testing in pediatric hematopoietic stem cell transplant recipients. *Pediatr Infect Dis J.* 2007;26:558-64.
47. **Alexander BD**, Byrne TC, Smith KL, Hanson KE, Anstrom KJ, Perfect JR, Reller LB. Comparative evaluation of Etest and Sensititre YeastOne Panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for antifungal susceptibility testing of *Candida* to seven antifungal agents. *J Clin Microbio.*

- 2007;45:698-706.
48. Gellad ZG, **Alexander BD**, Liu JK, Griffith BC, Meyer AM, Johnson JL, Muir AJ. Severity of *Clostridium difficile*-associated diarrhea in solid-organ transplant patients. *Transpl Infect Dis.* 2007;9: 276-280.
  49. Hanson KE, **Alexander BD**, Woods C, Petti C, Reller LB. Validation of laboratory screening criteria for Herpes Simplex Virus testing on cerebrospinal fluid. *J Clin Microbiol*, 2007;45:721-724.
  50. Smith PB, Benjamin DK, **Alexander BD**, Johnson MD, Steinbach WJ. 1→3 β-D glucan levels in healthy pediatric patients: preliminary data for use of the β glucan diagnostic assay in children. *Clin Vaccine Immunol* 2007;14:924-5.
  51. Bressler AM, Kaye KS, Lipuma JJ, **Alexander BD**, Moore CM, Reller LB, Woods CW. Risk factors for *Burkholderia cepacia complex* bacteremia among intensive care unit patients without cystic fibrosis: a case-control study. *Infect Control Hosp Epidemiol.* 2007;28:951-8.
  52. Cohen-Wolkowicz M, Benjamin DK, Fowler VG, Wade KC, **Alexander BD**, Worley G, Cotten CM, Goldstein RF, Dixon T, Wilfret D, Smith PB. Mortality and neurodevelopmental outcome following *Staphylococcus aureus* bacteremia in infants. *Pediatric Infect Dis .* 2007;26:1151-1166.
  53. Shepard JR, Addison RM, **Alexander BD**, Della-Latta P, Gherna M, Haase G, Hall G, Johnson JK, Merz WG, Peltroche-Llacsahuanga H, Stender H, Venezia RA, Wilson D, Procop GW, Wu F, Fiandaca MJ. Multicenter evaluation of the *Candida albicans/Candida glabrata* Peptide Nucleic Acid Fluorescent In Situ Hybridization method for simultaneous dual-color identification of *C. albicans* and *C. glabrata* directly from blood culture bottles. *J Clin Microbiol.* 2008;46:50-55.
  54. Singh N, **Alexander BD**, Lortholary O, Dromer F, Gupta KL, John GT, del Busto R, Klintmalm GB, Somani J, Lyon GM, Pursell K, Stosor V, Muñoz P, Limaye AP, Kalil AC, Pruett TL, Garcia-Diaz J, Humar A, Houston S, House AA, Wray D, Orloff S, Dowdy LA, Fisher RA, Heitman J, Wagener MM, Husain S. Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. *Clin Infect Dis.* 2008;46:e12-8.
  55. Kontoyiannis DP, Lewis RE, Lortholary O, **Alexander BD**, Dromer F, Gupta KL, John GT, Del Busto R, Klintmalm GB, Somani J, Lyon GM, Pursell K, Stosor V, Munoz P, Limaye AP, Kalil AC, Pruett TL, Garcia-Diaz J, Humar A, Houston S, House AA, Wray D, Orloff S, Dowdy LA, Fisher RA, Heitman J, Albert ND, Wagener MM, Singh N. Calcineurin-inhibitor agents interact synergistically with antifungal agents in vitro against *Cryptococcus neoformans* isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. *Antimicrob Agents Chemother.* 2008;52:735-8.
  56. **Alexander BD**, Petzold EW, Reller LB, Palmer SM, Davis RD, Woods CW, LiPuma JJ. Survival after lung transplantation of cystic fibrosis patients infected with *Burkholderia cepacia complex*. *Am J Transplant* 2008;8:1025-30.

57. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, Rex JH, **Alexander BD**, Andes D, Brown SD, Chaturvedi V, Ghannoum MA, Knapp CC, Sheehan DJ, Walsh TJ. Correlation of MIC with outcome for *Candida* species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. *J Clin Microbiol.* 2008;46:2620-9.
58. Singh N, Lortholary O, Dromer F, **Alexander BD**, Gupta KL, John GT, del Busto R, Klintmalm GB, Somani J, Lyon GM, Pursell K, Stosor V, Muñoz P, Limaye AP, Kalil AC, Pruett TL, Garcia-Diaz J, Humar A, Houston S, House AA, Wray D, Orloff S, Dowdy LA, Fisher RA, Heitman J, Wagener MM, Husain S and the Cryptococcal Collaborative Transplant Study Group. Central nervous system cryptococcosis in solid organ transplant recipients: clinical relevance of abnormal neuroimaging findings. *Transplantation* 2008;86:647-651.
59. **Alexander BD**, Perfect J, Daly J, Restrepo A, Tobon A, Patrino H, Hardalo C, Graybill J. Posaconazole as salvage therapy in patients with invasive fungal infections following solid organ transplant. *Transplantation*, 2008;86:791-796.
60. Ostrosky-Zeichner L, Rex JH, Pfaller MA, Diekema DJ, **Alexander BD**, Andes D, Brown SD, Chaturvedi V, Ghannoum MA, Knapp CC, Sheehan DJ, Walsh TJ. Rationale for reading fluconazole MICs at 24h rather than 48h when testing *Candida* spp. by the CLSI M27-A2 standard method. *Antimicrob Agents Chemother.* 2008;52:4175-7.
61. Shi S, Dodds Ashley ES, **Alexander BD**, Hickey AJ. Initial characterization of micafungin pulmonary delivery via two different nebulizers and multivariate data analysis of aerosol mass distribution profiles. *AAPS PharmSciTech.* 2009;10(1):129-37.
62. Balajee SA, Kano R, Baddley JW, Moser SA, Marr KA, **Alexander BD**, Andes D, Kontoyiannis DP, Perrone G, Peterson S, Brandt ME, Pappas PG, Chiller TM. Molecular identification of *Aspergillus* species: Transplant Associated Infection Surveillance Network (TRANSNET). *J Clin Microbiol.* 2009;47(10):3138-41.
63. Pfaller MA, Diekema DJ, Ghannoum A, Rex JH, **Alexander BD**, Andes D, Brown SD, Chaturvedi V, Espinel-Ingroff A, Fowler CL, Johnson EM, Knapp CC, Motyl MR, Ostrosky-Zeichner L, Sheehan DJ, Walsh TJ; for the Clinical and Laboratory Standards Institute Antifungal Testing Subcommittee. Wild Type MIC Distribution and epidemiological cutoff values for *Aspergillus fumigatus* and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. *J Clin Microbiol.* 2009;47(10):3142-6.
64. Sun HY, **Alexander BD**, Lortholary O, Dromer F, Forrest GN, Lyon GM, Somani J, Gupta KL, del Busto R, Pruett TL, Sifri CD, Limaye AP, John GT, Klintmalm GB, Pursell K, Stosor V, Morris MI, Dowdy LA, Muñoz P, Kalil AC, Garcia-Diaz J, Orloff S, House AA, Houston S, Wray D, Huprikar S, Johnson LB, Humar A, Razonable RR, Fisher RA, Husain S, Singh N. Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. *Clin Infect Dis* 2009;49(11):1721-8.
65. Osawa R, **Alexander BD**, Lortholary O, Dromer F, Forrest GN, Lyon GM, Somani J, Gupta

- KL, del Busto R, Pruett TL, Sifri CD, Limaye AP, John GT, Klintmalm GB, Pursell K, Stosor V, Morris MI, Dowdy LA, Muñoz P, Kalil AC, Garcia-Diaz J, Orloff S, House AA, Houston S, Wray D, Huprikar S, Johnson LB, Humar A, Razonable RR, Fisher RA, Husain S, Wagener MM, Singh N. Identifying predictors of central nervous system disease in solid organ transplant recipients with cryptococcosis. *Transplantation* 2010;89:69-74.
66. Nowell L, Moran C, Smith PB, Seed P, **Alexander BD**, Cotten CM, Wiener JS, Benjamin DK Jr. Prevalence of renal anomalies after urinary tract infections in hospitalized infants less than two months of age. *J Perinatol.* 2010;30(4):281-5.
67. Sun HY, **Alexander BD**, Lortholary O, Dromer F, Forrest GN, Lyon GM, Somani J, Gupta KL, del Busto R, Pruett TL, Sifri CD, Limaye AP, John GT, Klintmalm GB, Pursell K, Stosor V, Morris MI, Dowdy LA, Muñoz P, Kalil AC, Garcia-Diaz J, Orloff S, House AA, Houston S, Wray D, Huprikar S, Johnson LB, Humar A, Razonable RR, Fisher RA, Husain S, Wagener MM, Singh N and the Cryptococcal Collaborative Transplant Study Group. Cutaneous cryptococcosis in solid organ transplant recipients. *Med Mycol* 2010;48(6):785-91.
- \*68. Kontoyiannis DP, Marr KA, Park BJ, **Alexander BD**, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, Freifeld AG, Hadley S, Herwaldt LA, Kauffman CA, Knapp K, Lyon GM, Morrison VA, Patterson T, Perl TM, Schuster MC, Walker R, Wannemuehler KA, Wingard JR, Chiller TM, Pappas PG. Prospective Surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the TRANSNET Database. *Clin Infect Dis.* 2010;50(8):1091-100.  
**\*Winner of the Nakano Citation from the National Center for Emerging and Zoonotic Infectious Diseases**
69. Pappas PG, **Alexander BD**, Andes DR, Hadley S, Kauffman CA, Freifeld A, Anaissie EJ, Brumble L, Herwaldt L, Ito J, Kontoyiannis DP, Lyon GM, Marr KA, Morrison VA, Park BJ, Patterson T, Perl TM, Oster RA, Schuster M, Walker R, Walsh TJ, Wannemuehler KA, Chiller TM. Invasive fungal infections among organ transplant recipients in the United States: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). *Clin Infect Dis* 2010;50(8):1101-11.
70. Wulff-Burchfield E, Schell WA, Eckhart AE, Pollack MG, Hua Z, Rouse JL, Pamula VK, Srinivasan V, Benton JL, **Alexander BD**, Wilfret DA, Kraft M, Cairns C, Perfect JR, Mitchell TG. Microfluidic platform versus conventional real-time PCR for the detection of *Mycoplasma pneumoniae* in respiratory specimens. *Diagn Microbiol Infect Dis* 2010;67(1):22-29.
71. Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin DS, **Alexander BD**. Breakthrough invasive candidiasis on micafungin. *J Clin Microbiol* 2010;48(7):2373-80.
72. Baddley JW, Andes DR, Marr KA, Kontoyiannis DP, **Alexander BD**, Kauffman CA, Oster RA, Anaissie EJ, Walsh TJ, Schuster MA, Wingard JR, Patterson TF, Ito JI, Williams DO, Chiller T, Pappas PG, and TRANSNET Investigators. Factors associated with mortality in transplant patients with invasive aspergillosis. *Clin Infect Dis*



- 2010;50(12):1559-67.
73. **Alexander BD**, Smith PB, Davis RD, Perfect JR, Reller LB. The (1,3)beta-D-glucan test as an aid to the early diagnosis of invasive fungal infections following lung transplantation. *J Clin Microbiol* 2010;48:4083-8.
  74. Harrison E, Stahlberger T, Whelan R, Sugrue M, Wingard JR, **Alexander BD**, Follett SA, Bowyer P and Denning DW for the Aspergillus Technology Consortium (AsTeC). *Aspergillus* DNA contamination in blood collection tubes. *Diagn Microbiol Infect Dis* 2010;67(4):392-4.
  75. **Alexander BD**, Schell WA, Siston AM, Rao CY, Bower WA, Balajee SA, Howell DN, Moore, ZS, Noble-Wang J, Rhyne JA, Fleischauer AT, Maillard JM, Kuehnert M, Vikraman D Collins BH, Marroquin CE, Park BJ. Fatal *Apophysomyces elegans* infection transmitted by deceased donor renal allografts. *Am J Transplant* 2010;10:2161-2167
  76. Sun HY, **Alexander BD**, Lortholary O, Dromer F, Forrest GN, Lyon GM, Somani J, Gupta KL, del Busto R, Pruett TL, Sifri CD, Limaye AP, John GT, Klintmalm GB, Pursell K, Stosor V, Morris MI, Dowdy LA, Munoz P, Kalil AC, Garcia-Diaz J, Orloff SL, House AA, Houston SH, Wray D, Huprikar S, Johnson LB, Humar A, Razonable RR, Fisher RA, Husain S, Wagener MM, Singh N; Cryptococcal Collaborative Transplant Study Group. Unrecognized pretransplant and donor-derived cryptococcal disease in organ transplant recipients. *Clin Infect Dis* 2010;51:1062-9.
  77. Osawa R, **Alexander BD**, Forrest GN, Lyon GM, Somani J, Del Busto R, Pruett TL, Sifri CD, Limaye AP, Klintmalm GB, Pursell K, Stosor V, Morris MI, Dowdy LA, Kalil AC, Garcia-Diaz J, Orloff SL, Houston SH, Wray D, Huprikar S, Johnson LB, Razonable RR, Fisher RA, Wagener MM, Husain S, Singh N. Geographic differences in disease expression of cryptococcosis in solid organ transplant recipients in the United States. *Ann Transplant* 2010;15:77-83.
  78. **Alexander BD**, Winkler TP, Shuai S, Dodds Ashley ES, Hickey AJ. Nebulizer delivery of micafungin aerosols. *Pharmacotherapy* 2011;31:52-7.
  79. Pfaller MA, Andes D, Arendrup MC, Diekema DJ, Espinel-Ingroff A, **Alexander BD**, Brown SD, Chaturvedi V, Fowler CL, Ghannoum MA, Johnson EM, Knapp CC, Motyl MR, Ostrosky-Zeichner L, Walsh TJ. Clinical breakpoints for voriconazole and *Candida* spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. *Diagn Microbiol Infect Dis*. 2011;70:330-43.
  80. Hauser PM, Bille J, Lass-Flörl C, Geltner C, Feldmesser M, Levi M, Patel H, Muggia V, **Alexander BD**, Hughes M, Follett SA, Cui X, Leung F, Morgan G, Moody A, Perlin DS, Denning DW. Multicenter, prospective clinical evaluation of respiratory samples from subjects at risk for *Pneumocystis jirovecii* infection by use of a commercial real-time PCR assay. *J Clin Microbiol*. 2011;49:1872-8.
  81. **Alexander BD**, Winkler TP, Shuai S, Dodds Ashley ES, Hickey AJ. Nebulizer delivery of liposomal amphotericin B aerosols. *Pharm Dev Technol*. 2011;16(6):577-82. PMID:21699390

82. Rosentul DC, Plantinga TS, Scott WK, **Alexander BD**, van de Geer NM, Perfect JR, Kullberg BJ, Johnson MD, Netea MG. The impact of caspase-12 on susceptibility to candidemia. *Eur J Clin Microbiol Infect Dis*. 2012;31(3):277-80. PMID:21706251
83. Pfeiffer CD, Samsa GP, Schell WA, Reller LB, Perfect JR, **Alexander BD**. Quantitation of *Candida* colony forming units in initial positive blood cultures. *J Clin Microbiol*. 2011;49(8):2879-83. PMID:21677065
84. Rosentul DC, Plantinga TS, Oosting M, Scott WK, Velez Edwards DR, Smith PB, **Alexander BD**, Yang JC, Laird GM, Joosten LA, van der Meer JW, Perfect JR, Kullberg BJ, Netea MG, Johnson MD. Genetic Variation in the Dectin-1/CARD9 Recognition Pathway and Susceptibility to Candidemia. *J Infect Dis*. 2011;204:1138-45. PMID:21881131
85. Park BJ, Pappas PG, Wannemuehler KA, **Alexander BD**, Anaissie EJ, Andes DR, Baddley JW, Brown JM, Brumble LM, Freifeld AG, Hadley S, Herwaldt L, Ito JI, Kauffman CA, Lyon GM, Marr KA, Morrison VA, Papanicolaou G, Patterson TF, Perl TM, Schuster MG, Walker RM, Wingard JR, Walsh TJ, Kontoyiannis DP. Invasive non-*Aspergillus* mold infections in transplant recipients, United States, 2001-2006. *Emerging Infectious Diseases* 2011;17(10):1855-64. PMID:22000355
86. Lease ED, **Alexander BD**. Fungal diagnostics in pneumonia. *Semin Respir Crit Care Med*. 2011;32(6):663-72. PMID:22167394
87. Johnson MD, Plantinga TS, van de Vosse E, Velez Edwards DR, Smith PB, **Alexander BD**, Yang JC, Kremer D, Laird GM, Oosting M, Joosten LA, van der Meer JW, van Dissel JT, Walsh TJ, Perfect JR, Kullberg BJ, Scott WK, Netea MG. Cytokine gene polymorphisms and the outcome of invasive candidiasis: a prospective cohort study. *Clin Infect Dis*. 2012;54(4):502-10. PMID:22144535
88. Plantinga TS, Johnson MD, Scott WK, van de Vosse E, Velez Edwards DR, Smith PB, **Alexander BD**, Yang JC, Kremer D, Laird GM, Oosting M, Joosten LAB, van der Meer JWM, van Dissel JT, Walsh TJ, Perfect JR, Kullberg BJ, Netea MG. Toll-like receptor 1 polymorphisms increase susceptibility to candidemia. *J Infect Dis*. 2012;205(6):934-43. PMID:22301633
89. Schell WA, Benton JL, Smith PB, Poore M, Rouse JL, Boles DJ, Johnson MD, **Alexander BD**, Pamula VK, Eckhardt AE, Pollack MG, Benjamin DK Jr, Perfect JR, Mitchell TG. Evaluation of a digital microfluidic real-time PCR platform to detect DNA of *Candida albicans* in blood. *Eur J Clin Microbiol Infect Dis*. 2012;31(9):2237-45 PMID:22327343
90. Singh N, Huprikar S, Burdette SD, Morris MI, Blair JE, Wheat LJ; **American Society of Transplantation, Infectious Diseases Community of Practice, Donor-Derived Fungal Infection Working Group**. Donor-derived fungal infections in organ transplant recipients: guidelines of the American Society of Transplantation, infectious diseases community of practice. *Am J Transplant*. 2012;12(9):2414-28. PMID:22694672
91. Hanson KE, Pfeiffer C, Lease E, Zaas A, Perfect J and **Alexander BD**. Randomized Comparison of  $\beta$ -D-glucan Surveillance with Preemptive Anidulafungin versus Standard Care for the Management of Invasive Candidiasis in Intensive Care Unit Patients: A Pilot

- Study. PLoS One. 2012;7(8):e42282. PMID:22879929
92. Dodds Ashley E, Drew R, Johnson M, Danna R, Dabrowski D, Lee S, Maschio M, Prasad M, **Alexander BD**, Papadopoulos G, Perfect JR. Cost of treating invasive fungal infection in the era of new fungal diagnostics and expanded antifungal treatment options. *Pharmacotherapy* 2012;32(10):890-901. PMID:23033228
93. Westervelt JD, **Alexander BD**, Costa SF, Miller SE, Howell DN, Smith SR. Detection of BK polyomavirus after kidney transplantation: a comparison of urine electron microscopy with plasma polymerase chain reaction. *Clin Transplant*. 2013;27(1):E42-8. PMID:23278388
94. **Alexander BD**, Johnson MD, Ortigosa CJ, Catania J, Pfeiffer CD, Castanheira M, Messer SA, Perlin DS, Pfaller MA, Increasing echinocandin resistance in *Candida glabrata*: clinical failure correlates with presence of *FKS* mutation and elevated MIC. *Clin Infect Dis*. 2013;56(12):1724-32. PMID: 23487382
- \*Editor's Choice: Echinocandin resistance is increasing among *Candida glabrata* while current consensus guidelines encourage the use of echinocandins as first-line therapy for this infection. The need for routine susceptibility testing of echinocandins for *C. glabrata* to guide therapeutic decision making is underscored. Editorial Commentary:** Luis Ostrosky-Zeichner. *Candida glabrata* and *FKS* mutations: Witnessing the emergence of the true multidrug-resistant *Candida*
95. Lyon GM, Abdul-Ali D, Loeffler J, White PL, Wickes B, Herrera ML, **Alexander BD**, Baden L, Clancy C, Denning D, Nguyen MH, Sugrue M, Wheat LJ, Wingard JR, Patterson TF, Caliendo AM. Development and evaluation of a calibrator material for nucleic acid-based assays for diagnosing aspergillosis. *J Clin Micro* 2013;51(7):2403-5. PMID: 23616459
96. Lionakis MS, Swamydas M, Fischer BG, Plantinga TS, Johnson MD, Jaeger M, Green NM, Masedunskas A, Weigert R, Mikelis C, Wan W, Lee CC, Lim JK, Rivollier A, Yang JC, Laird GM, Wheeler RT, **Alexander BD**, Perfect JR, Gao JL, Kullberg BJ, Netea MG, Murphy PM. CX3CR1-dependent renal macrophage survival promotes *Candida* control and host survival. *J Clin Invest*. 2013;123:5035-51. PMID: 24177428
97. Doligalski CT, Harris MT, Zaas D, **Alexander BD**. Epidemiology of invasive mold infections in lung transplant recipients. *Am J Transplant*. 2014 Apr 11 (Epub ahead of print] PMID:24726020
98. Barker A., Horan J, Slechta E, **Alexander BD**, and Hanson K. Complexities associated with the molecular and proteomic identification of *Paecilomyces* in the clinical mycology laboratory. *Med Mycol*. 2014 Mar 30. [Epub ahead of print] PMID:24687961
99. Kauffman CA, Freifeld AG, Andes DR, Baddley JW, Herwaldt L, Walker RC, **Alexander BD**, Anaissie EJ, Benedict K, Ito JI, Knapp KM, Lyon GM, Marr KA, Morrison VA, Park BJ, Patterson TF, Schuster MG, Chiller TM, Pappas PG. Endemic fungal infections in solid organ and hematopoietic cell transplant recipients enrolled in the Transplant Associated Infection Surveillance Network. *Transpl Infect Dis*. 2014;16(2):213-24. PMID:24589027

100. Rosentul DC, Plantinga TS, Farcas M, Oosting M, Hamza OJ, Scott WK, **Alexander BD**, Yang JC, Laird GM, Joosten LA, van der Meer JW, Perfect JR, Kullberg BJ, van der Ven AJ, Johnson MD, Netea MG. Role of autophagy genetic variants for the risk of *Candida* infections. *Med Mycol.* 2014;52(4):333-41. PMID:24713404
101. Wheat LJ, Nguyen MH, **Alexander BD**, Denning D, Caliendo AM, Lyon GM, Baden LR, Marty FM, Clancy C, Kirsch E, Noth P, Witt J, Sugrue M, Wingard JR. Long-term stability at -20 degrees C of *Aspergillus* galactomannan in serum and bronchoalveolar lavage specimens. *J Clin Microbiol.* 2014;52(6):2108-11. PMID:24719449
102. Lamoth F and **Alexander BD**. Non-molecular methods for the diagnosis of respiratory fungal infections. *Clin Lab Med.* 2014;34(2):315-336. PMID: 24856530
103. Horan JL, Stout JE, **Alexander BD**. Hepatitis B core antibody-positive donors and cardiac transplantation. *Transpl Infect Dis.* 2014;16(5):859-63. PMID: 25154437
104. Sun HY, **Alexander BD**, Huprikar S, Forrest GN, Bruno D, Lyon GM, Wray D, Johnson LB, Sifri CD, Razonable RR, Morris MI, Stoser V, Wagener MM, Singh N. Predictors of immune reconstitution syndrome in organ transplant recipients with cryptococcosis: implications for the management of immunosuppression. *Clin Infect Dis.* 2015 Jan 1;60(1):36-44. PMID: 25210020
105. Lamoth F, **Alexander BD**, Juvvadi PR, Steinbach WJ. Antifungal activity of compounds targeting the Hsp90-calcineurin pathway against various mould species. *J Antimicrob Chemother.* 2015;70(5):1408-11. PMID: 25558076
106. Lamoth F and **Alexander BD**. Antifungal activity of SCY-078 (MK-3118) and standard antifungal agents against clinical non-*Aspergillus* mold isolates. *Antimicrob Agents Chemother.* 2015; 59(7):4308-11. PMID: 25896696
107. McCarty TP, Baddley JW, Walsh TJ, **Alexander BD**, Kontoyiannis DP, Perl TM, Walker R, Patterson TF, Schuster MG, Lyon GM, Wingard JR, Andes DR, Park BJ, Brandt ME, Pappas PG; TRANSNET Investigators. Phaeohyphomycosis in transplant recipients: Results from the Transplant Associated Infection Surveillance Network (TRANSNET). *Med Mycol.* 2015;53:440-6. PMID: 25908651
108. Lamoth F and **Alexander BD**. Comparing Etest and broth microdilution for antifungal susceptibility testing of the most relevant pathogenic molds. *J Clin Microbiol.* 2015 Oct;53(10):3176-81. PMID: 26202113
109. Brasier AR, Zhao Y, Spratt HM, Wiktorowicz JE, Ju H, Wheat LJ, Baden L, Stafford S, Wu Z, Issa N, Caliendo AM, Denning DW, Soman K, Clancy CJ, Nguyen MH, Sugrue MW, **Alexander BD**, Wingard JR. Improved Detection of Invasive Pulmonary Aspergillosis Arising during Leukemia Treatment Using a Panel of Host Response Proteins and Fungal Antigens. *PLoS One.* 2015 Nov 18;10(11):e0143165. PMID: 26581097
110. Swamydas M, Gao JL, Break TJ, Johnson MD, Jaeger M, Rodriguez CA, Lim JK, Green NM, Collar AL, Fischer BG, Lee CC, Perfect JR, **Alexander BD**, Kullberg BJ, Netea MG, Murphy PM, Lionakis MS. CXCR1-mediated neutrophil degranulation and fungal killing promote *Candida* clearance and host survival. *Sci Transl Med.* 2016 Jan

- 20;8(322):322ra10. PMID: 26791948
111. Husain S, Sole A, **Alexander BD**, Aslam S, Avery RK, Benden C, Billaud EM, Chambers D, Danziger-Isakov L, Fedson S, Gould K, Gregson A, Grossi P, Hadjiliadis D, Hopkins P, Luong ML, Marriott DJ, Monforte V, Muñoz P, Pasqualotto AC, Roman A, Silveira FP, Teuteberg J, Weigt S, Zass AK, Zuckerman A, Morrissey O. The 2015 International Society for Heart and Lung Transplantation guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: Executive summary. *J Heart Lung Transplant*. 2016;35(3):261-82. PMID: 26970469
  112. Lamoth F; Damonti L; **Alexander BD**. Role of antifungal susceptibility testing in non-*Aspergillus* invasive mold infections. *J Clin Microbiol*. 2016;54(6):1638-40. PMID: 27008871
  113. Healey KR, Zhao Y, Perez WB, Lockhart SR, Sobel JD, Farmakiotis D, Kontoyiannis DP, Sanglard D, Taj-Aldeen SJ, **Alexander BD**, Jimenez-Ortigosa C, Shor E, Perlin DS. Prevalent mutator genotype identified in fungal pathogen *Candida glabrata* promotes multi-drug resistance. *Nat Commun*. 2016;7:11128. PMID: 27020939
  114. Abril MK, Barnett AS, Wegermann K, Fountain E, Strand A, Heyman BM, Blough BA, Swaminathan AC, Sharma-Kuinkel B, Ruffin F, **Alexander BD**, McCall CM, Costa SF, Arcasoy MO, Hong DK, Blauwkamp TA, Kertesz M, Fowler VG Jr, Kraft BD. Diagnosis of *Capnocytophaga canimorsus* Sepsis by Whole-Genome Next-Generation Sequencing. *Open Forum Infect Dis*. 2016 Jul 12;3(3): ofw144. PMID: 27704003
  115. Hemmersbach-Miller M, Duronville J, Sethi S, Miller SE, Howell DN, Henshaw N, **Alexander BD**, Roberts JK. Hemorrhagic Herpes Simplex Virus Type 1 (HSV-1) nephritis: an unusual cause of acute allograft dysfunction. *American Journal of Transplantation* 2017;17(1):287-291. PMID: 27545820
  116. Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, Pikiš A, Razonable RR, Miller V, Griffiths PD; Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials. Disease Definitions Working Group of the **Cytomegalovirus Drug Development Forum**. *Clin Infect Dis*. 2017;64(1):87-91. PMID: 27682069
  117. Schell WA, Jones AM, Garvey EP, Hoekstra WJ, Schotzinger RJ, **Alexander BD**. Fungal CYP51 Inhibitors VT-1161 and VT-1129 exhibit strong in vitro activity against *Candida glabrata* and *C. krusei* isolates clinically resistant to azole and echinocandin antifungal compounds. *Antimicrob Agents Chemother*. 2017;61(3) e01817-16. PMID: 27956419
  118. Lamoth F; Damonti L, Chung J, **Alexander BD**. Changing epidemiology of invasive mold infections in patients receiving azole prophylaxis. *Clinical Infectious Diseases*, 2017;64(11):1619-1621. PMID: 28199491
  119. Lockhart SR, Ghannoum MA, **Alexander BD**. Establishment and use of epidemiological cutoff values for molds and yeasts using the Clinical and Laboratory Standards Institute M57 standard. *J Clin Microbiol*. 2017;55(5):1262-1268. PMID: 28202791

120. Baker AW, Lewis SS, **Alexander BD**, Chen LF, Wallace RJ, Brown-Elliott B, Isaacs PJ, Pickett LC, Patel CB, Smith PK, Reynolds JR, Wolfe CR, Milano CA, Schroder JN, Davis RD, Hartwig MG, Stout JE, Strittholt N, Maziarz EK, Saullo JH, Hazen KC, Walczak RJ, Vasireddy R, Vasireddy S, McKnight CM, Anderson DJ, Sexton DJ. Two-phase outbreak of *Mycobacterium abscessus*: investigation and mitigation. *Clin Infect Dis*. 2017;64(7):902-911. PMID: 28077517
121. Schell WA, Jones AM, Borroto-Esoda K, **Alexander BD**. Antifungal activity of SCY-078 and standard antifungal agents against 178 clinical isolates of resistant and susceptible *Candida* species. *Antimicrob Agents Chemother*. 2017;61(11): e01102-17. PMID: 28827419
122. Revankar AG, Baddley JW, Chen SC, Kauffman CA, Slavin, M, Vazquez JA, Seas C, Morris MI, Nguyen MH, Shoham S, Thompson GR, **Alexander BD**, Simkins J, Ostrosky-Zeichner L, Mullane K, Alangaden G, Andes DR, Cornely OA, Wahlers K, Lockhart SR, Pappas PG. A Mycoses Study Group international prospective study of phaeohyphomycosis: an analysis of 99 proven/probable cases. *Open Forum Infectious Diseases*, Volume 4, Issue 4, 1 October 2017, ofx200, <https://doi.org/10.1093/ofid/ofx200>. PMID: 29766015
123. Natori Y, Alghamdi A, Tazari M, Miller V, Husain S, Komatsu T, Griffiths P, Ljungman P, Orchanian-Cheff A, Kumar D, Humar A; **CMV Consensus Forum**. Use of Viral Load as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Meta-analysis. *Clin Infect Dis*. 2018;66(4):617-631. PMID: 29020339
124. Messina JA, Sinha R, Starr K, Arshad M, **Alexander BD**, Chao NJ, Sung AD. Clinical and genomic characterization of recurrent enterococcal bloodstream infection in patients with acute leukemia. *Open Forum Infect Dis*. 2018 May 5;5(6):ofy107. doi: 10.1093/ofid/ofy107. eCollection 2018 Jun. PMID: 29977964
125. Messina JA, Wolfe CR, Hemmersbach-Miller M, Milano C, Todd JL, Reynolds J, **Alexander BD**, Schell WA, Cuomo CA, Perfect JR. Genomic characterization of recurrent mold infections in thoracic transplant recipients. *Transpl Infect Dis*. 2018 Oct; 20(5):e12935. PMID: 29851203
126. Mullane KM, Winston DJ, Nooka A, Morris MI, Stiff P, Dugan MJ, Holland H, Gregg K, Adachi JA, Pergam SA, **Alexander BD**, Dubberke ER, Broyde N, Gorbach SL, Sears PS. A randomized, placebo-controlled trial of fidaxomicin for prophylaxis of *Clostridium difficile* associated diarrhea in adults undergoing hematopoietic stem cell transplantation. *Clin Infect Dis*. 2019;68(2):196-203. PMID: 29893798
127. Chung SJ, Miller RA, Permpalung N, Baker AW, Maxwell P, Diehl LF, Rizzeri DA, **Alexander BD**. Fluoroquinolone prophylaxis reduces febrile neutropenia bloodstream infectious from mucosal translocations, and intensive care admissions in high risk hematological patents, a single center experience. *Leukemia and Lymphoma*. 2019;60(2):488-492. PMID: 30126315
128. Hemmersbach-Miller M, **Alexander BD**, Sudan DL, Pieper C, Schmader KE. Single-

- center analysis of infectious complications in older adults during the first year after kidney transplantation. *Eur J Clin Microbiol Infect Dis*. 2019 Jan;38(1):141-148. PMID: 30353487
129. Baker A, Maziarz E, Arnold C, Johnson M, Workman AD, Reynolds J, **Alexander BD**. Invasive fungal Infection after lung transplantation: epidemiology in the setting of antifungal prophylaxis. *Clin Infect Dis*. 2020;70(1):30-39. PMID: 30801642
130. Baker AW, **Alexander BD**. Reply to Authors (Drs. Marinelli and Rotstein). *Clin Infect Dis*. 2021 Jan 27;72(2):366-367. PMID: 33501960
131. Hemmersbach-Miller M, **Alexander BD**, Sudan DL, Pieper C, Schmader KE. Infections after kidney transplantation. Does age matter? *Clin Transplant*. 2019;33(4):e13516. PMID: 30849194
132. Sears CL, File TM, **Alexander BD**, McQuillen DP, MacIntyre AT, Allen UD, Colasanti JA, Siddiqui J, Reveles KR, Busky C. Charting the Path Forward: Development, Goals and Initiatives of the 2019 Infectious Diseases Society of America Strategic Plan. Infectious Diseases Society of America (IDSA) Board of Directors. *Clin Infect Dis*. 2019 Nov 27;69(12):e1-e7. PMID: 31620782
133. Permpalung N, Thaniyavarn T, Saullo JL, Arif S, Miller RA, Reynolds JM, **Alexander BD**. Oral and Inhaled Ribavirin Treatment for Respiratory Syncytial Virus Infection in Lung Transplant Recipients. *Transplantation*. 2020 Jun;104(6):1280-1286. PMID: 31568275
134. Saullo JL, Li Y, Messina JA, Thompson J, Dalton T, Giri VK, Reed SD, Miller R, Horwitz ME, **Alexander BD**, Sung AD. Cytomegalovirus in Allogeneic Hematopoietic Transplantation: Impact on Costs and Clinical Outcomes Using a Preemptive Strategy. *Biol Blood Marrow Transplant*. 2020 Mar;26(3):568-580. PMID: 31712193
135. Hemmersbach-Miller M, **Alexander BD**, Pieper CF, Schmader KE. Age matters: older age as a risk factor for CMV reactivation in the CMV serostatus-positive kidney transplant recipient. *Eur J Clin Microbiol Infect Dis*. 2020;39(3):455-463. PMID: 31758441
136. Stemler J, Salmanton-García J, Seidel D, **Alexander BD**, Bertz H, Hoenigl M, Herbrecht R, Meintker L, Meißner A, Mellinghoff SC, Sal E, Zarrouk M, Koehler P, Cornely OA. Risk factors and mortality in invasive *Rasamsonia* spp. infection: Analysis of cases in the FungiScope® registry and from the literature. *Mycoses*. 2020;63(3):265-274. PMID: 31769549
137. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, Clancy CJ, Wingard JR, Lockhart SR, Groll AH, Sorrell TC, Bassetti M, Akan H, **Alexander BD**, Andes D, Azoulay E, Bialek R, Bradsher RW, Bretagne S, Calandra T, Caliendo AM, Castagnola E, Cruciani M, Cuenca-Estrella M, Decker CF, Desai SR, Fisher B, Harrison T, Heussel CP, Jensen HE, Kibbler CC, Kontoyiannis DP, Kullberg BJ, Lagrou K, Lamoth F, Lehrnbecher T, Loeffler J, Lortholary O, Maertens J, Marchetti O, Marr KA, Masur H, Meis JF, Morrissey CO, Nucci M, Ostrosky-Zeichner L, Pagano L, Patterson TF, Perfect JR, Racil Z, Roilides E, Ruhnke M, Prokop CS, Shoham S, Slavin

- MA, Stevens DA, Thompson GR, Vazquez JA, Viscoli C, Walsh TJ, Warris A, Wheat LJ, White PL, Zaoutis TE, Pappas PG. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. *Clin Infect Dis*. 2020 Sep;71(6):1367-1376. PMID: 31802125
138. Baker AW, Maziarz EK, Lewis SS, Stout JE, Anderson DJ, Smith PK, Schroder JN, Daneshmand MA, **Alexander BD**, Wallace RJ, Sexton DJ, Wolfe CR. Invasive *Mycobacterium abscessus* complex infection after cardiac surgery: epidemiology, management, and clinical outcomes. *Clin Infect Dis*. 2021 Apr;72(7):1232-1240. PMID: 32133489
139. Sears, CL, Powderly WG, Auwaerter PG, **Alexander BD**, File TM. Pathways to Leadership: Reflections of Recent Infectious Diseases Society of America (IDSA) Leaders During the Conception and Launch of the Inclusion, Diversity, Access and Equity Movement within the IDSA. *J Infect Dis*. 2020;222(Supplement 6):S554-S559. PMID: 32926740
140. Miller RA, **Alexander BD**. Editorial: Infections of the immunocompromised host: a musing on the changing times. *Curr Opin Infect Dis*. 2020 Aug;33(4):279-280. PMID: 32657963
141. **Alexander BD**, Lamoth F, Heussel CP, Prokop CS, Desai SR, Morrissey CO, Baddley JW. Guidance on Imaging for Invasive Pulmonary Aspergillosis and Mucormycosis: From the Imaging Working Group for the Revision and Update of the Consensus Definitions of Fungal Disease from the EORTC/MSGERC. *Clin Infect Dis*. 2021 Mar;72(Supplement\_2):S79-S88. PMID: 33709131
142. Eichenberger EM, Ruffin F, Dagher M, Lerebours R, Jung SH, Sharma-Kuinkel B, Macintyre AN, Thaden JT, Sinclair M, Hale L, Kohler C, Palmer SM, **Alexander BD**, Fowler VG Jr, Maskarinec SA. Bacteremia in solid organ transplant recipients as compared to immunocompetent patients: Acute phase cytokines and outcomes in a prospective, matched cohort study. *Am J Transplant*. 2021;21(6):2113-2122. PMID: 33131212
143. Steinbrink JM, Myers RA, Hua K, Johnson MD, Seidelman JL, Tsalik EL, Henao R, Ginsburg GS, Woods CW, **Alexander BD**, McClain MT. The host transcriptional response to candidemia is dominated by neutrophil activation and heme biosynthesis and supports novel diagnostic approaches. *Genome Med*. 2021 Jul 5;13(1):108. PMID: 34225776
144. Heldman MR, Kates OS, Safa K, Kotton CN, Georgia SJ, Steinbrink JM, **Alexander BD**, Hemmersbach-Miller M, Blumberg EA, Crespo MM, Multani A, Lewis AV, Eugene Beard O, Haydel B, La Hoz RM, Moni L, Condor Y, Flores S, Munoz CG, Guitierrez J, Diaz EI, Diaz D, Vianna R, Guerra G, Loebe M, Rakita RM, Malinis M, Azar MM, Hemmige V, McCort ME, Chaudhry ZS, Singh P, Hughes K, Velioglu A, Yabu JM, Morillis JA, Mehta SA, Tanna SD, Ison MG, Tomic R, Candace Derenge A, van Duin D, Maximin A, Gilbert C, Goldman JD, Sehgal S, Weisshaar D, Girgis RE, Nelson J, Lease



- ED, Limaye AP, Fisher CE; UW COVID-19 SOT Study Team. COVID-19 in hospitalized lung and non-lung solid organ transplant recipients: A comparative analysis from a multicenter study. *Am J Transplant*. 2021 Aug;21(8):2774-2784. PMID: 34008917
145. Steinbrink JM, Myers RA, Hua K, Johnson MD, Seidelman JL, Tsalik EL, Henao R, Ginsburg GS, Woods CW, **Alexander BD**, McClain MT. The host transcriptional response to candidemia is dominated by neutrophil activation and heme biosynthesis and supports novel diagnostic approaches. *Genome Med*. 2021 Jul 5;13(1):108. PMID: 34225776
146. Heldman MR, Kates OS, Safa K, Kotton CN, Georgia SJ, Steinbrink JM, **Alexander BD**, Hemmersbach-Miller M, Blumberg EA, Multani A, Haydel B, La Hoz RM, Moni L, Condor Y, Flores S, Munoz CG, Guitierrez J, Diaz EI, Diaz D, Vianna R, Guerra G, Loebe M, Rakita RM, Malinis M, Azar MM, Hemmige V, McCort ME, Chaudhry ZS, Singh PP, Hughes Kramer K, Velioglu A, Yabu JM, Morillis JA, Mehta SA, Tanna SD, Ison MG, Derenge AC, van Duin D, Maximin A, Gilbert C, Goldman JD, Lease ED, Fisher CE, Limaye AP; UW COVID-19 SOT Study Team. Changing trends in mortality among solid organ transplant recipients hospitalized for COVID-19 during the course of the pandemic. *Am J Transplant*. 2021 Sep 12. Online ahead of print. PMID: 34514710
147. Wingard JR, **Alexander BD**, Baden LR, Chen M, Sugrue MW, Leather HL, Caliendo AM, Clancy CJ, Denning DW, Marty FM, Nguyen MH, Wheat LJ, Logan BR, Horowitz MM, Marr KA. Impact of Changes of the 2020 Consensus Definitions of Invasive Aspergillosis on Clinical Trial Design: Unintended Consequences for Prevention Trials? *Open Forum Infect Dis*. 2021 Sep;8 (10):ofab441. doi: 10.1093/ofid/ofab441. PMID: 34631917
148. Narayanasamy S, Williams AR, Schell WA, Moehring RW, **Alexander BD**, Le T, Bharadwaj RA, McGauvran M, Schroder JN, Perfect JR. *Curvularia alcornii* aortic pseudoaneurysm following aortic valve replacement: case report and review of the literature. *Open Forum Infect Dis*. 2021 Nov;8 (11), <https://doi.org/10.1093/ofid/ofab536>.
149. Avery RK, Alain S, **Alexander BD**, Blumberg EA, Chemaly RF, Cordonnier C, Duarte RF, Florescu DF, Kama N, Kumar D, Maertens J, Marty FM, Papanicolaou GF, Silveira FP, Witzke O, Jingyang W, Sundberg AK, Fournier M for the SOLSTICE Trial Investigators. Maribavir for refractory Cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial. *Clin Infect Diseases*. 2021 Dec, Online ahead of print. PMID: 34864943
150. Heldman MR, Kates OS, Safa K, Kotton CN, Multani A, Georgia SJ, Steinbrink JM, **Alexander BD**, Blumberg EA, Haydel B, Hemmige V, Hemmersbach-Miller M, La Hoz RM, Moni L, Condor Y, Flores S, Munoz CG, Guitierrez J, Diaz EI, Diaz D, Vianna R, Guerra G, Loebe M, Yabu JM, Kramer KH, Tanna SD, Ison MG, Rakita RM, Malinis M, Azar MM, McCort ME, Singh PP, Velioglu A, Mehta SA, van Duin D, Goldman JD, Lease ED, Wald A, Limaye AP, Fisher CE; UW Covid-19 SOT Study Team. Delayed mortality among solid organ transplant recipients hospitalized for COVID-19. *Clin Infect*

*Dis.* 2022 Feb 25: Online ahead of print. PMID: 35212363

151. Safety of Inhaled Amphotericin B Lipid Complex as Antifungal Prophylaxis in Lung Transplant Recipients. Huggins JP, Pease R, Stanly K, Workman A, Reynolds J, **Alexander BD**. *Antimicrob Agents Chemother.* 2022 May 4:e0028322. doi: 10.1128/aac.00283-22. Online ahead of print. PMID: 35506698

### Refereed Publications - Articles in Press

None

### Refereed Publications – Articles Submitted

None

### Non-Refereed Publications - Articles in Print

1. **Alexander BD**. Fungal infections in heart and lung transplant recipients. *Current Treatment Options in Infectious Diseases* 2001;3:543-551.
2. **Alexander BD**. Prophylaxis of invasive mycoses in solid organ transplantation. *Current Opinion in Infectious Diseases* 2002;15(6):583-589.
3. Zaas A and **Alexander B**. New developments in the diagnosis and treatment of infections in lung transplant recipients. *Resp Care Clin of North America* 2004;10(4):531-547.
4. Dodds Ashley ES and **Alexander BD**. Posaconazole. *Drugs of Today* 2005;41(6):393-400.
5. Radack KP and **Alexander BD**. Prophylaxis of invasive mycoses in solid organ transplantation. *Curr Infect Dis Rep.* 2009;11(6):427-34.
6. Person AK, Konytoyianis DP, **Alexander BD**. Fungal Infections in transplant and oncology patients. *Infect Dis Clin of North Am.* 2010;24(2):439-59.
7. Lease ED and **Alexander BD**. Fungal diagnostics in pneumonia. *Semin Respir Crit Care Med* 2011;3.

### Book Chapters

1. **Alexander, BD**. Infectious complications and considerations in the liver transplant recipient. In Eds. Killenberg PG, Clavien PA. Medical Care of the Liver Transplant Patient, Second Edition (pp.308-323). Malden MA: Blackwell Science, 1997.
2. **Alexander BD**, Fishman JA. Prophylaxis in solid organ transplantation. In Eds. Marr KA, Thorner AR. UpToDate. Wellesley, MA: UpToDate, 2001.
3. **Alexander, BD** and Hanson KE. Infectious complications and considerations in the liver transplant recipient. In Eds. Killenberg PG, Clavien PA. Medical Care of the Liver Transplant Patient, Third Edition. Malden, MA: Blackwell Science, 2006.
4. **Alexander BD** and Schell WA. Hyalohyphomycosis. In Eds. Mandell GL, Kauffman CA. Atlas of Fungal Infections, Second Edition (pp. 253-266). Philadelphia: Current Medicine, Inc, 2006.
5. Costa, SF and **Alexander, BD**. Epidemiology and clinical manifestations of *Scedosporium* infection. In Eds. Kauffman CA, Thorner AR. UpToDate. Wellesley, MA: UpToDate,

- 2007.
6. Costa, SF and **Alexander, BD**. Diagnosis and treatment of *Scedosporium* infection. In Eds. Kauffman CA, Thorner AR. UpToDate. Wellesley, MA: UpToDate, 2007.
  7. Zaas AK and **Alexander BD**. The spectrum of disease: invasive pulmonary aspergillosis. In Eds. Latgé JP, Steinbach WJ. Aspergillus fumigatus and Aspergillosis (pp.293-299). Herndon, VA: ASM Press, 2008.
  8. Hanson KE, **Alexander BD**, Perfect J. Drug resistance in *Cryptococcus neoformans*. In Eds. Sobel JD, Mayer, Oulette, Lerner. Antimicrobial Resistance (pp. 967-986). New York, NY: Springer US, 2009.
  9. Costa, SF and **Alexander BD**. Epidemiology of fungal infections: what, where, and when. In Eds. Ghannoum MA, Perfect JR. Antifungal Therapy. (pp.11-48). New York, NY: InformaHelathcareUSA, Inc., 2010.
  10. Costa, SF and **Alexander BD**. Antifungal management in risk groups: transplant recipients. In Eds. Ghannoum MA, Perfect JR. Antifungal Therapy (pp.367-385). New York, NY: InformaHelathcareUSA, Inc., 2010.
  11. Pfeiffer CD, Perfect JR, **Alexander BD**. Current controversies in the treatment of fungal infections. Ed. Safdar A. Management of Infections in Cancer Patients (Chapter 27; pp.301-316). Totowa, NJ: Humana Press, 2011.
  12. Singh N, **Alexander BD**. Cryptococcosis in transplant recipients. In Eds. Heitman J, Kozel T, Kwon-Chung J, Perfect J, Casadevall A. Cryptococcus: From Human Pathogen to Model Yeast (Chapter 37). Herndon, VA: ASM Press, 2010.
  13. Perfect JR, **Alexander BD**, Schell WA. Phaeohyphomycoses. In Eds. Dismukes WE, Kauffman CA. Clinical Mycology, Second Edition (pp.305-321). New York, NY: Springer Publishing, 2011.
  14. Horan JL, Perfect JR, **Alexander BD**. Invasive fungal disease in transplant populations: overview. Ed. Safdar A. Principles and Practice of Transplant Infectious Diseases. New York, NY: Springer Publishing, 2012.
  15. Horan JL and **Alexander BD**. Opportunistic mycoses. In Eds. Broaddus VC, Gotway M, Shreiner J, Ernst JD, King TE, Lazarus SC, Mason RJ, Murray JF, Nadel JA, Slutsky AS. Murray & Nadel's Textbook of Respiratory Medicine (Chapter 38). Elsevier Inc., 2016.
  16. Lamoth F, Costa SF and **Alexander BD**. Epidemiology of fungal infections: what, where, and when. In Eds. Ghannoum MA, Perfect JR. Antifungal Therapy. New York, NY: InformaHelathcareUSA, Inc., 2018.
  17. Chung J, Costa SF and **Alexander BD**. Antifungal management in risk groups: solid organ transplant recipients. In Eds. Ghannoum MA, Perfect JR. Antifungal Therapy. New York, NY: InformaHelathcareUSA, Inc., 2018.
  18. Fishman JA, Costa SF, and **Alexander BD**. Infection in Kidney Transplant Recipients. In Eds. Knechtle S, Morris PJ. Kidney Transplantation-Principles and Practice, 8<sup>th</sup> Edition Elsevier Inc., 2018.

19. Arif SA, Costa S, **Alexander BD**. Infections in Heart transplantation. In Eds. Khorsandi M, Haratwig M, Danesmad M, Dark J, Kirk A, Tsui S, Milano C. Oxford Specialist Handbook: Cardiopulmonary Transplantation and Mechanical Circulatory Support. Submitted, July, 2019.

#### Non-authored Publications

1. Litvintseva AP, Kestenbaum L, Vilgalys R, Mitchell TG. Comparative analysis of environmental and clinical populations of *Cryptococcus neoformans*. *J Clin Microbiol* 2005;43:556-64.
2. Salmanton-García J, Koehler P, Kindo A, Falces-Romero I, García-Rodríguez J, Ráčil Z, Chen SC, Klimko N, Desoubeaux G, Thompson GR, III, Benítez-Peñuela MÁ, Rodríguez JY, Sheppard DC, Hoenigl M, Le Govic Y, Badali H, Baddley JW, Chander J, Ingram PR, Pakstis DL, Mellinshoff SC, Atıcı S, Cesaro S, Chakrabarti A, Dupont D, González GM, Hatvani L, Herbrecht R, Klyasova G, Lass-Flörl C, Mareş M, Mullane K, Vinh DC, Wisplinghoff H, Lackner M, Cornely OA, Seidel D; **ECMM/ISHAM working group**. Needles in a haystack: Extremely rare invasive fungal infections reported in FungiScope® Global Registry for Emerging Fungal Infections. *J Infect*. 2020 Nov;81(5):802-815. PMID: 32798532

#### Other Publications (Editorials, Book Reviews, Publications for Mass Distribution, White Papers)

1. **Alexander B**. Book Review: Ed. Greene JN. Infections in cancer patients. New York: Marcel Dekker, Inc. 2004. *Clin Infect Dis* 2004;40:640-641.
2. **Alexander BD**. Cryptococcosis after solid organ transplantation. (Editorial). *Transpl Infect Dis* 2005;7(1):1-3.
3. Freifeld A, Wingard J, **Alexander BD**. Zygomycosis in an allogeneic transplant patient. *Antifungal Options – Interdisciplinary Perspectives on Key Pathogens* 2005;4:1-7.
4. **Alexander BD**, Perfect JR, Sawyer R. *Aspergillus* infection in a solid organ transplant patient. *Antifungal Options–Interdisciplinary Perspectives on Key Pathogens* 2006;5:1-7.
5. Patterson TF, **Alexander BD**. Invasive candidiasis: current trends and clinical challenges. *Hospital Physician – Special Report*. Wayne, PA; Turner White Communications. [www.turner-white.com](http://www.turner-white.com); 2006;1-12.
6. **Co-Author**. CLSI Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard – third edition. CLSI document M27-A3. Wayne PA: Clinical and Laboratory Standards Institute; April 2008.
7. **Co-Author**. CLSI Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard – second edition. CLSI document M38-A2. Wayne PA: Clinical and Laboratory Standards Institute; April 2008.
8. Marr KA, **Alexander BD**, Wheat J, Pappas PG for the Mycoses Study Group. White Paper: FDA / EMEA - Statement of need and impact of a qualified biomarker on clinical drug development of treatments for invasive aspergillosis. July 2008.

9. **Lead Author.** CLSI, Method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline – second edition. CLSI document M44-A2. Wayne PA: Clinical and Laboratory Standards Institute; August 2009
10. **Co-Author.** CLSI, Method for antifungal disk diffusion susceptibility testing of filamentous fungi; approved guideline. CLSI document M51-A. Wayne PA: Clinical and Laboratory Donor-derived fungal infections in organ transplant recipients: May 2010
11. **Alexander BD.** White Paper: NIAID Genome Sequencing Centers for Infectious Diseases – Statement of need for whole genome sequencing of subjects enrolled in the Aspergillus Technology Consortium Repository. December 2012.
12. **Contributing Writer:** The 2014 *International Society for Heart and Lung Transplantation* guidelines for management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: executive summary.
13. **Contributor.** CLSI. Principles and Procedures for the Development of Epidemiological Cutoff Values for Antifungal Susceptibility Testing (Proposed Draft). 1st ed. CLSI guideline M57 (Proposed Draft). Wayne, PA: Clinical and Laboratory Standards Institute; 2016
14. **Contributor.** CLSI. Method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline – third edition. CLSI document M44-A3. Wayne PA: Clinical and Laboratory Standards Institute; June 2017
15. **Contributor.** CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard – fourth edition. CLSI document M27-A4. Wayne PA: Clinical and Laboratory Standards Institute; June 2017.
16. **Contributor.** CLSI. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard – third edition. CLSI document M38-A3. Wayne PA: Clinical and Laboratory Standards Institute; June 2017
17. **Contributor.** CLSI. Performance Standards for antifungal susceptibility testing of filamentous fungi. CLSI document M61 (M38S/M51S). Wayne PA: Clinical and Laboratory Standards Institute; June 2017.
18. **Co-Author.** CLSI. Performance standards for antifungal susceptibility testing of yeasts. CLSI document M60 (M27S/M44S). Wayne PA: Clinical and Laboratory Standards Institute; June 2017.
19. **Contributor.** CLSI. Epidemiological cutoff values for antifungal susceptibility testing. 3<sup>rd</sup> ed. CLSI supplement M59. Wayne,PA: Clinical and Laboratory Standards Institute; June 2020.
20. **Contributor.** CLSI. Performance standards for antifungal susceptibility testing of yeasts. 2nd ed. CLSI supplement M60. Wayne, PA: Clinical and Laboratory Standards Institute; June 2020.
21. **Contributor.** CLSI. Performance standards for antifungal susceptibility testing of filamentous fungi. 2nd ed. CLSI supplement M61. Wayne, PA: Clinical and Laboratory Standards Institute; June 2020.
22. Miller RA and **Alexander BD (Editors).** Infections of the immunocompromised host: a

musings on the changing times. In Current Opinion in Infectious Diseases, Infections of the Immunocompromised Host. August 2020 - Volume 33 - Issue 4 - p 279-280.

### Abstracts

1. **Alexander BD**, Schell W, Cox G. Lobomycosis: A search for the pathogen. Abstract presented 21 May 1996, Duke University Medical Center Resident Research Forum, Durham, NC.
2. **Alexander BD**, Stout JE, Reller LB, Hamilton CD. Accuracy of clinical assessment at an academic medical center in recognition of tuberculosis in a high-incidence area for MOTT. Abstract 379Sa. Presented 13 November 1998, 36<sup>th</sup> Annual meeting of the Infectious Diseases Society of America, Denver, CO.
3. **Alexander BD**, Stout JE, Reller LB, Hamilton CD. Hospital management of patients suspected of pulmonary TB in a high-incidence area for MOTT. Abstract 156339. Presented 26 April 1999, American Lung Association/American Thoracic Society International Meeting, San Diego, CA.
4. **Alexander BD**, Palmer SM, Tapson VF, Davis RD, Reller LB. Bacteremia and fungemia in lung transplant recipients at Duke University Medical Center. Abstract 101578. Presented 28 April 1999, American Lung Association/American Thoracic Society International Conference, San Diego, CA.
5. Singh N, Linden P, Munoz P, Dominguez EA, Kusne S, Snyderman D, **Alexander BD**, Tollermar J, Hsieh M, Yu C. Emerging trends in invasive mold infections in organ transplant recipients. Abstract 1327. Presented 18 September 2000, 40<sup>th</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada.
6. Stout JE, McDonald Jr., Engemann JJ, **Alexander BD**, Hamilton CD. Conditions associated with pulmonary non-tuberculous mycobacteria (NTM) in a tertiary care hospital in the southeastern U.S. Abstract 200199. Presented 8 September 2000, 38<sup>th</sup> Annual meeting of the Infectious Disease Society of America, New Orleans, LA.
7. Bressler A, Woods C, Kaye K, **Alexander BD**, Moore C. *Burkholderia cepacia* bacteremia: epidemiology and outcomes at a university hospital. Abstract 223. Presented 26 October 2001, 39<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA.
8. Singh N, Avery RK, Munoz P, **Alexander BD**, Pruett T, Jacobs R, Tollemar JG, Dominguez EA, Yu CM, Paterson DL, Wagener MM, Kusne S, Linden P. Trends in risk-profiles and mortality due to invasive aspergillosis in liver transplant recipients. Abstract #M867, 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 27-30, 2002.
9. Husain S, John GT, **Alexander BD**, Gupta KL, DelBusto R, Stoser V, Dominguez EA, Pruett T, Garcia-Diaz J, Jacobs R, House A, Orloff S, Limaye AP, Houston S, Heitman J, Singh N. Changing spectrum of *Cryptococcus neoformans* infection in organ transplant recipients in the era of calcineurin-inhibitor (Tacrolimus and Cyclosporine A) based immunosuppression. Abstract M884, 42nd Interscience Conference on Antimicrobial

- Agents and Chemotherapy, San Diego, CA, September 27-30, 2002.
10. John GT, **Alexander BD**, Gupta KL, DelBusto R, Pruett T, Dominguez EA, Jacobs R, Orloff S, Limaye AP, House A, Stoser V, Garcia-Diaz J, Houston S, Heitman J, Singh N. Characteristics and outcome of *Cryptococcus neoformans* infection of the central nervous system in organ transplant recipients: a prospective, multicenter study. Abstract M885, 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 27-30, 2002.
  11. Zaas AK, Boyce M, Schell W, **Alexander Lodge B**, Perfect JR. *Rhodotorula* fungemia: Clinical outcomes and in vitro antifungal susceptibilities. Abstract M900, 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 27-30, 2002.
  12. Paya CV for the **Valganciclovir SOT Study Group**. A randomized, double-blind, double-dummy, active-comparator controlled, multi-center study of the efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of CMV disease in 372 high-risk (D+/R-) heart, liver, and kidney recipients. Abstract LB-4, 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 27-30, 2002
  13. Karchmer AW, Pappas P, Merion R, Cloud G, Hadley S, Rabkin J, Schuster M, Andes D, Kauffman C, Delaney J, Daly J, Kusne S, **Alexander BD**, for the MSG STUDY #44 NIAID Sponsored Mycoses Study Group. Invasive fungal infection in liver transplant recipients (LTR) considered at low risk. Abstract, 40<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America, Chicago, IL, October 24-27, 2002.
  14. Ashley ED, **Alexander BD**, Perfect JR, Drew RH, Cost-avoidance associated with infectious diseases clinical research. Abstract 160, American College of Clinical Pharmacy Spring Research Forum, Palm Springs, California, April 27-30, 2003.
  15. Wilson DA, Joyce MJ, Hall LS, **Alexander Lodge B**, Reller LB, Roberts GD, Hall GS, Procop GW. Multicenter evaluation of a *Candida albicans* PNA FISH probe in blood cultures that contained yeast. Abstract C-162, 103<sup>rd</sup> General Meeting of the American Society for Microbiology, Washington, DC, May 18-22, 2003.
  16. Freeman RB, Macey K, Paya C, Pescovitz MD, Humar A, Dominguez, Washburn K, Blumberg E, **Alexander B**, Heaton N, and Valganciclovir Solid Organ Transplant Study Group. Risk Factors for cytomegalovirus (CMV) disease: results from a multicenter randomized trial of valganciclovir. Abstract 932, 4<sup>th</sup> Annual Meeting of the American Transplant Congress, Washington, DC, May 30 – June 4, 2003.
  17. Pescovitz MD, Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, **Alexander B**, Freeman R, Heaton N, Woodruffe-Peacock C, Macey K, Tansley R, and Valganciclovir Study Group. Valganciclovir for prevention of CMV disease: 12 month follow up of a randomized trial of 364 D+/R- transplant recipients. Abstract 575, 4<sup>th</sup> Annual Meeting of the American Transplant Congress, Washington, DC, May 30 – June 4, 2003.
  18. Wiltshire H, Hirankarn S, Farrell C, Paya C, Pescovitz MD, Humar A, Dominguez E, Washburn K, Blumberg E, **Alexander B**, Freeman R, Heaton N, and Valganciclovir Solid Organ Transplant Study Group. Pharmacokinetics of ganciclovir after its oral

- administration and from its pro-drug, valganciclovir, in solid organ transplant recipients. Abstract 933, 4<sup>th</sup> Annual Meeting of the American Transplant Congress, Washington, DC, May 30 – June 4, 2003.
19. Humar A, Paya C, Pescovitz MD, Dominguez E, Washburn K, Blumberg E, **Alexander B**, Freeman R, Heaton N, Woodruffe C, Mueller B, Macey K, and Tansley R. Clinical utility of cytomegalovirus (CMV) viral load testing for predicting CMV disease in high risk D+/R- solid organ transplant recipients. Abstract 1054, 4<sup>th</sup> Annual Meeting of the American Transplant Congress, Washington, DC, May 30 – June 4, 2003.
  20. Humar A, Paya C, Pescovitz MD, Dominguez E, Washburn K, Blumberg E, **Alexander B**, Freeman R, Heaton N, Woodruffe-Peacock C, Mueller B, Macey K, Tansley R, and Valganciclovir Study Group. CMV virologic outcomes in D+/R- solid organ transplant recipients receiving valganciclovir vs. ganciclovir prophylaxis. Abstract 1086, 4<sup>th</sup> Annual Meeting of the American Transplant Congress, Washington, DC, May 30 – June 4, 2003.
  21. Boivin G, Goyette N, Gilbert C, Pescovitz M, Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, **Alexander B**, Freeman R, Heaton N, Tansley R, Roberts N, Covington E, and Valganciclovir Study Group. Valganciclovir prophylaxis is not associated with the emergence of cytomegalovirus UL97 and UL54 resistance mutations in solid organ transplant recipients: results from a multicenter trial. Abstract 1090, 4<sup>th</sup> Annual Meeting of the American Transplant Congress, Washington, DC, May 30 – June 4, 2003.
  22. Wiltshire H, Paya C, Pescovitz MD, Humar A, Dominguez E, Washburn K, Blumberg E, **Alexander B**, Freeman R, Heaton N, Tansley R, and Valganciclovir Solid Organ Transplant Study Group. Pharmacodynamics of safety and efficacy for ganciclovir after its oral administration and from its pro-drug, valganciclovir, in solid organ transplant recipients. Abstract 1396, 4<sup>th</sup> Annual Meeting of the American Transplant Congress, Washington, DC, May 30 – June 4, 2003.
  23. Ostrosky-Zeichner L, **Alexander B**, Kett D, Vazquez J, Pappas P, Saeki F, Ketchum PA, Wingard JR, Schiff RA, Tamura H, Finkelman MA, Rex JH. Multicenter clinical evaluation of the (1→3) β—Glucan (BG) Assay (GlucateLL™) as an aid to diagnosis of invasive fungal infections in humans. Abstract M1034a, 43<sup>rd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 14-17, 2003.
  24. Blankenship J, Husain S, DelBusto R, **Alexander B**, Limaye A, Dowdy L, Humar A, Stoser V, Pruett T, Jacobs R, John G, Gupta K, Diaz J, Fisher R, House A, Orloff S, Houston S, Klintmalm G, Heitman J, Singh N. Temperature sensitive phenotypic characteristics and resistance to calcineurin inhibitors (tacrolimus or cyclosporin A) in *Cryptococcus neoformans*: correlation with tissue tropism in organ transplant recipients. Abstract M398, 43<sup>rd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 14-17, 2003.
  25. Pappas PG, Morgan J, Hajjeh RA and the **Transplant Associated Infection Surveillance Network (TRANSNET)**. Prospective surveillance for invasive fungal infections in hematopoietic stem cell and solid organ transplant recipients in the United States. Abstract M1010, 43<sup>rd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy,



- Chicago, IL, September 14-17, 2003.
26. Johnson MD, **Alexander BD**, Perfect JR, Smith LL, Kaye KS. Epidemiology and mortality of nosocomial candidemia with stratification according to age: poor prognosis for the elderly. Abstract M1000, 43<sup>rd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 14-17, 2003.
  27. Bressler A, Kaye K, LiPuma J, Reller LB, **Alexander BD**, Moore C, Woods, C. Risk Factors for *Burkholderia cepacia* bacteremia in patients without cystic fibrosis. Abstract 577, 41<sup>st</sup> Annual Meeting of Infectious Diseases Society of America, San Diego, CA, October 9-12, 2003
  28. Ostrosky-Zeichner L, Sable C, Sobel J. **Alexander B**, Donowitz G, Kan V, Kauffman C, Kett D, Larsen R, Morrison V, Nucci M, Pappas P, Bradley M, Major S, Wallace D, Rex J. Multicenter retrospective development and validation of a clinical prediction rule for invasive candidiasis in the intensive care setting. Abstract 51, 14<sup>th</sup> Annual Focus on Fungal Infections Conference, New Orleans, LA, March 24-26, 2004.
  29. **Alexander B**, Wills E, Reller L, Yow E, Palmer S, Davis R, Woods C, LiPuma J. Survival following lung transplantation of cystic fibrosis patients infected with *Burkholderia cepacia* complex. Abstract 91, Annual Meeting of the International Society for Heart & Lung Transplantation, San Francisco, CA, April 21-24, 2004.
  30. **Alexander B**, Palmer S, Wills E, Reller L, Yow E, Davis R, Woods C, LiPuma J. Pre-transplant infection with *Burkholderia cenocepacia* is the foremost determinant of one-year survival in cystic fibrosis patients after lung transplant. Abstract 4298, 100<sup>th</sup> American Thoracic Society International Conference, Orlando FL, May 21-26, 2004.
  31. Safdar N, Andes D, Schuster M, Hadley S, **Alexander B**, Somani J, Brumble L, Kauffman C, Pappas P. Epidemiology and risk factors associated with *Candida non-albicans* infection in organ transplant recipients: prospective surveillance results from the TRANSNET database. Abstract 682, 42<sup>nd</sup> Annual Meeting of Infectious Diseases Society of America, Boston MA, September 30-October 3, 2004.
  32. Pappas P, **Alexander B**, Marr K, Kontoyiannis D, Hadley S, Ito J, Morrison V, Morgan J, Fridkin S, Oster R, Daram P, Walsh T. Invasive fungal infections in hematopoietic stem cell and organ transplant recipients: overview of the TRANSNET database. Abstract 671, 42<sup>nd</sup> Annual Meeting of Infectious Diseases Society of America, Boston MA, September 30-October 3, 2004.
  33. Baddley J, Park B, Marr K, Andes D, Kontoyiannis D, Hadley S, Schuster M, **Alexander B**, Walsh T, Oster R, Pappas P, and the TRANSNET investigators. Factors influencing mortality in transplant recipients with invasive aspergillosis. Abstract 673, 42<sup>nd</sup> Annual Meeting of Infectious Diseases Society of America, Boston MA, September 30-October 3, 2004.
  34. Andes DR, Safdar N, Hadley S, **Alexander B**, Schuster M, Somani J, Brumble L, Kauffman C, Morrison V, Pappas P. Epidemiology of invasive candida infections in solid and hematologic transplantation: prospective surveillance results from the TRANSNET database. Abstract M1014, 44<sup>th</sup> Interscience Conference on Antimicrobial Agents and

- Chemotherapy, Washington, DC, October 30-November 2, 2004.
35. Zaas AK, Dodds ES, **Alexander BD**, Johnson MD, Perfect JR. Caspofungin for invasive candidiasis: experience at DUMC 2001-2004. Abstract M1015, 44<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October 30-November 2, 2004.
  36. Singh N, Husain S, **Alexander B**, John G, Gupta L, DelBusto R, Limaye A, Stoser V, Pursell K, Munoz P, and the Cryptococcus Collaborative Study Group. Impact of immunosuppressive regimen on mortality in organ transplant recipients with *C. neoformans* infection. Abstract M1017, 44<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October 30-November 2, 2004.
  37. Singh N, Munoz P, Forrest G, **Alexander B**, Brennan K, Somani J, Husain S. *Scedosporium* infections in organ transplant recipients: impact of antifungal agent therapy on outcome. Abstract M1018, 44<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October 30-November 2, 2004.
  38. Morgan J, **Alexander B**, Wannemuehler K, Fan K, Daram P, Marr K, Kontoyiannis D, Kauffman C, Ito J, Hadley S, Fridkin S, Pappas P, Walsh T, and the TRANSNET Investigators. Quantification of risk for invasive fungal infections among transplant recipients reporting to TRANSNET. Abstract 1058, 44<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October 30-November 2, 2004.
  39. Miller R, Park B, Fridkin S, Morrison V, Pappas P, **Alexander B**, Schuster M, Diekema D, and TRANSNET Investigators. Characterization of very late onset aspergillosis among organ transplant recipients. Abstract 744, 43<sup>rd</sup> Annual Meeting of Infectious Diseases Society of America, San Francisco CA, October 6-9, 2005.
  40. Andes D, Safdar N, **Alexander B**, Fridkin S, Hadley S, Kauffman C, Brumble L, Schuster M, Walker R, Pappas P, and TRANSNET Investigators. Comparative epidemiology of invasive *Candida* infections among organ transplant recipients: prospective surveillance results from the CDC TRANSNET database. Abstract 741, 43<sup>rd</sup> Annual Meeting of Infectious Diseases Society of America, San Francisco CA, October 6-9, 2005.
  41. Hadley S, Pappas P, Lyon M, **Alexander B**, Kauffman C, Andes D, Freifeld A, Fan K, Morgan J, and TRANSNET Investigators. *Cryptococcus neoformans* infections among solid organ transplant recipients reporting to TRANSNET. Abstract 736, 43<sup>rd</sup> Annual Meeting of Infectious Diseases Society of America, San Francisco CA, October 6-9, 2005.
  42. Hanson K, Castellano C, **Alexander B**, Woods C, Petti C, Reller L B. Validation of laboratory screening criteria for HSV PCR testing on CSF. Abstract 129/958, 43<sup>rd</sup> Annual Meeting of Infectious Diseases Society of America, San Francisco CA, October 6-9, 2005.
  43. **Alexander BD**, Perfect J, Daly J, Restrepo A, Tobon A, Patino H, Hardalo C, Graybill J. Posaconazole as salvage therapy in patients with invasive fungal infections following solid organ transplant. Abstract M959, 45<sup>th</sup> Interscience Conference on Antimicrobial

- Agents and Chemotherapy, Washington, DC, December 16-19, 2005.
44. Singh N, Lortholary O, **Alexander BD**, Husain S, and the Crypto Collaborative Transplant Study Group. Antifungal management practices and evolution of infection in organ transplant recipients with *C. neoformans* infection. Abstract M966, 45<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, December 16-19, 2005.
  45. Dodds Ashley ES, Petry NA, Drew RH, **Alexander BD**, Palmer SM, Coleman RE, Perfect JR. Characterization of aerosolized amphotericin B lipid complex lung distribution. Abstract presented 17 December 2005, Society of Infectious Diseases Pharmacists, Washington, DC.
  46. Smith PB, Benjamin DK, **Alexander BD**, Johnson MD, Steinbach WJ. 1→3 β-D glucan levels in healthy pediatric patients. Abstract presented, Pediatric Academic Societies' Annual Meeting, San Francisco, CA, April 29-May 2, 2006.
  47. Smith PB, Schell WA, Johnson MD, **Alexander BD**, Benjamin DK, Perfect JR, Mitchell TG. Detection of *Candida albicans* and *Candida parapsilosis* DNA in blood by real-time PCR. Abstract presented, 106<sup>th</sup> General Meeting, American Society for Microbiology, Orlando FL, 21-25 May 2006.
  48. Gellad ZG, **Alexander BD**, Liu JK, Griffith BC, Meyer AM, Johnson JL, Muir AJ. Severity of *Clostridium difficile*-associated diarrhea in solid-organ transplant patients. Abstract presented 23 June 2006, Duke University Medical Center Resident Research Forum, Durham, NC. (Recipient, Best Poster Award)
  49. Fann W, Della-Latta P, Addison R, **Alexander B**, Procop G, Wilson D, Merz W, Gherna M. Dual color PNA FISH assay for simultaneous identification of *Candida albicans* and *Candida glabrata* directly from positive blood culture bottles. Abstract, 44<sup>th</sup> Annual Meeting of Infectious Diseases Society of America, Toronto, Canada, October 12-15, 2006.
  50. Cohen-Wolkowicz M, Benjamin D, Fowler V, Wade K, **Alexander B**, Worley G, Dixon T, Wilfret D, Smith PB. Neonatal *Staphylococcus aureus* bacteremia in the neonatal intensive care unit: is there a role for daptomycin? Abstract 5904, Pediatrics Academic Societies' Annual Meeting, Toronto, Canada, May 5-8, 2007.
  51. Singh N, **Alexander BD**, Lortholary O, Gupta KL, Husain S and the Cryptococcal Transplant Study Group; Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. Abstract M2024, 47<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20, 2007.
  52. Park BJ, Pappas PG, Marr KA, Anaissie EJ, Ito J, **Alexander BD**, Walsch TJ, Kontoyiannis DP. Recent epidemiology of zygomycosis among organ transplant and stem cell transplant recipients: results from the TRANSNET surveillance network. Abstract M618, 47<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20, 2007.
  53. Patterson TF, Kirkpatrick WR, **Alexander BD**, Danziger L, Freifeld A, Goff D, Greene J,

- High K, Ippoliti C, Landovitz R, Madinger N, Magalhaes-Silverman M, Pankey G, Pitrak D, Schuster M, Segal BH, Turett G, Vance E, Wingard J, Graybill JR. Efficacy and safety of caspofungin in a real world clinical setting. Abstract M1179, 47<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20, 2007.
54. Pappas PG, Kauffman C, **Alexander B**, Andes D, Hadley S, Patterson T, Walker R, Morrison V, Perl T, Wannemuehler K, Chiller T. Prospective surveillance of invasive fungal infections among organ transplant recipients in the U.S. 2001-2006: review of TRANSNET. Abstract M1195, 47<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20, 2007.
55. Dodds, ES, Petry A, Davies JD, Zaas DW, Palmer SM, Shipes, SW, Drew RH, **Alexander BD**, Coleman RE, Perfect JR. Aerosolized amphotericin B lipid complex distribution in lung transplant recipients: a comparison of continuous versus breath actuated nebulizers. Abstract M1165, 47<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20, 2007.
56. Baddley JW, Marr, KA, Andes DA, Kontoyiannis DP, Patterson TF, Anaissie EJ, Walsh TJ, **Alexander BD**, Schuster M, Oster RA, Pappas PG. Epidemiology of *Aspergillus terreus* infection in transplant recipients from Transplant Associated Infection Surveillance Network. Abstract 175, 45<sup>th</sup> Annual Meeting of Infectious Diseases Society of America, San Diego, CA, October 4-7, 2007.
57. **Alexander BD**, Hoang JK, Chen LF, Baddley JW, Patz EF. Computed tomography findings of invasive pulmonary aspergillosis in lung transplant recipients. Abstract 58, 18<sup>th</sup> Annual Focus on Fungal Infections Conference, San Antonio, TX, March 5-7, 2008.
58. Dodds Ashley, E, Drew R, Johnson M, R. Danna R, Dabrowski D, Lee S, Maschio M, Prasad M, **Alexander B**, Papadopoulos G, Perfect J. The institutional cost of treating invasive aspergillosis at a single US center: comparison between infected and non-infected individuals. Abstract 27, 18<sup>th</sup> Annual Focus on Fungal Infections Conference, San Antonio, TX, March 5-7, 2008.
59. Hanson KE, Costa SF, **Alexander BD**. The utility of surveillance bronchoscopy for the detection of subclinical infection after lung transplantation. Abstract 31, 15<sup>th</sup> Annual International Symposium on Infections in the Immunocompromised Host, Thessaloniki, Greece, June 22-25, 2008.
60. Vallor AC, **Alexander BD**, Kirkpatrick WR, Najvar LK, Bocanegra R, Wingard J, Patterson TF. Influence of time and repeated freeze-thaw cycles on the quantification of *Aspergillus* in animal tissue samples as assessed by real time PCR. Abstract M-698, 48<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy/46<sup>th</sup> Infectious Diseases Society of America Joint Meeting Session, Washington, DC, October 25-28, 2008.
61. Harrison E, Bowyer P, Sugrue MW, **Alexander BD**, Perlin DS, Denning DW, Wingard JR. Fungal DNA contamination of blood collection tubes. Abstract M-2148, 48<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy/46<sup>th</sup> Infectious Diseases Society

- of America Joint Meeting Session, Washington, DC, October 25-28, 2008.
62. Singh N, Forrest G, Sifri C, **Alexander B**, Johnson L, Lyon M, Lortholary O. *Cryptococcus*-associated immune reconstitution syndrome in solid organ transplant recipients: results from a prospective, multicenter study. Abstract D-1095, 48<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy/46<sup>th</sup> Infectious Diseases Society of America Joint Meeting Session, Washington, DC, October 25-28, 2008.
  63. Siston AM, Rao CY, Bower WA, Moore Z, Noble-Wang J, Balajee A, Rhyne J, Fleischauer A, Maillard JM, Kuehnert M, **Alexander BD**, Park BJ. A cluster of renal transplant-associated zygomycosis – South Carolina and North Carolina, 2009. Abstract, Epidemic Intelligence Service Conference, Atlanta, GA, April 20-24, 2009.
  64. Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin DS, **Alexander BD**. Breakthrough invasive candidiasis on micafungin. Abstract M1243, Oral Presentation, 49<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 12-15, 2009.
  65. Sun H, **Alexander BD**, Lortholary O, Singh N, and the Cryptococcal Collaborative Transplant Group. Cutaneous Cryptococcosis in solid organ transplant recipients in the current era. Abstract M1039, 49<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 12-15, 2009.
  66. Sun H, **Alexander BD**, Lortholary O, Singh N, and the Cryptococcal Collaborative Transplant Group. Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Abstract M1038, 49<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 12-15, 2009.
  67. Bone S, Johnson C, Walraven A, Smith PB, **Alexander BD**, Perfect JR, Johnson MD. Mortality rates among adults with candidemia are unchanged over the last decade. Abstract M1009, 49<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 12-15, 2009.
  68. Pfeiffer CD, Zaas AK, Moseley MA, Thompson W, Perfect JR, **Alexander BD**. Plasma proteomics for invasive candidiasis diagnosis. Abstract M1682, Featured poster for Poster Walk Session, 49<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 12-15, 2009.
  69. Pfaller, MA, Diekema DJ, Ghannoum MA, Rex JH, **Alexander BD**, Andes D, Brown, SD, Chaturvedi V, Epinel-Ingroff A, Fowler CL, Johnson EM, Knapp CC, Motyl MR, Ostrosky-Zeichner L, Sheehan DJ, Walsh TJ for the Clinical and Laboratory Standards Institutes (CLSI) Antifungal Testing Subcommittee. Wild-type minimum inhibitory concentration distribution and epidemiological cutoff values for *Aspergillus fumigatus* and triazoles using CLSI method. Abstract M1716, 49<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 12-15, 2009.
  70. **Alexander BD**, Andes DR, Harrison J, Dubberke ER, Kontoyiannis DP, Pappas PG, Baddley JW. CT findings of invasive pulmonary aspergillosis in solid organ transplant recipients. Abstract 406, 47<sup>th</sup> Annual Meeting of Infectious Diseases Society of America,

Philadelphia, PA, October 29-November 1, 2009.

71. Plantinga TS, Johnson MD, van der Velden W, Rosentul D, Giamarellos-Bourboulis EJ, Ferwerda B, Smith PB, **Alexander BD**, Joosten LA, van der Meer J, Donnelly P, Perfect JR, Blijlevens N, Kullberg BJ, Netea MG. Genetic variants of dectin-1 and susceptibility to infections with *Candida* spp. Abstract 2130, Oral Presentation, 20th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 10-13, 2010.
72. Johnson MD, Plantinga TS, Scott WK, van de Vosse E, Velez Edwards DR, Smith PB, **Alexander BD**, Yang JC, Laird G, Oosting M, van der Meer J, van Dissel J, Kullberg BJ, Netea MG, Perfect JR. Functional IL-10 and IL-12B polymorphisms are associated with persistent *Candida* spp. bloodstream infection. Abstract 2018, Oral Presentation, 20th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 10-13, 2010.
73. Pfeiffer CD, Samsa GP, Schell WA, Perfect JR, **Alexander BD**. Quantitation of *Candida* colony forming units in initial positive blood cultures. Abstract M398/420, 50<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, September 12-15, 2010.
74. **Alexander BD**, Feldmesser M, Bille J, Lass-Flörl C, Cui S, Moody A, Denning D. Multinational, prospective evaluation of commercial *Pneumocystis* Real-Time (RT) PCR test. Abstract M417a/439, 50<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, September 12-15, 2010.
75. Plantinga TS, Johnson MD, Scott WK, van De Vosse E, Verlez-Edwards DR, Smith PB, **Alexander BD**, Yang JC, Kremer D, Laird GM, Oosting M, Joosten LAB, van Der Meer JWM, van Dissel J, Walsh TJ, Perfect JR, Kullberg BJ, Netea MG. Genetic variants of TLR1 increase susceptibility to candidemia. Abstract M1309, 50<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, September 12-15, 2010.
76. Osawa R, **Alexander BD**, Singh N. Geographic differences in disease expression of cryptococcosis in solid organ transplant (SOT) recipients in the United States (US). Abstract 648, 48<sup>th</sup> Annual Meeting of Infectious Diseases Society of America, Vancouver, BC, Canada, October 21-24, 2010.
77. Doligalski CT, Harris MT, Zaas D, **Alexander BD**. Invasive mold infections in lung transplant recipients: risk factor analysis and epidemiology. Abstract, University HealthSystem Consortium Pharmacy Council Meeting, Anaheim, CA, December 5, 2010.
78. Sun H, Forrest G, **Alexander BD**, Bruno D, Singh N Predictors of Immune Reconstitution Syndrome (IRS) in Transplant Recipients with Cryptococcosis. Abstract M1138 oral presentation, 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago IL, September 19, 2011.
79. McCarty T, Baddley J, **Alexander BD**, Kontoyiannis D, Marr KA, Park B, Perl TM, Schuster M, Walker RC, Walsh TJ, Pappas P. Phaeohyphomycosis and scedosporiosis in transplant recipients: Results from the Transplant Associated Infection Surveillance

- Network (TRANSNET). Abstract 527, IDWeek 2012, San Diego, CA, October 17-21, 2012.
80. Baker AW, Maziarz EK, Arnold CJ, **Alexander BD**. Invasive candidiasis following lung transplantation surgery. Abstract F740, ICAAC 2015, San Diego, CA, September 17-21, 2015.
  81. Schell WA, Garvey EP, Hoekstra WJ, Schotzinger RJ, **Alexander BD**. Investigational CYP51 inhibitors VT-1161 and VT-1129 show strong in vitro activity against *Candida glabrata* isolates clinically resistant to azole and echinocandin compounds. Abstract F740, ICAAC 2015, San Diego, CA, September 17-21, 2015.
  82. Baker AW, Lewis SS, **Alexander BD**, Isaacs PJ, Pickett LC, Wallace RJ, Brown-Elliott BA, Strittholt N, Hazen KC, Wolfe CR, Maziarz EK, Saullo JH, Davis RD, Reynolds JM, Anderson D, Sexton DJ, Chen, LF. A cluster of *Mycobacterium abscessus* among lung transplant patients: investigation and mitigation. Abstract 627. Oral presentation IDWeek 2015, San Diego, CA, October 8-11, 2015.
  83. Lamoth, F, Damonti, L, **Alexander BD**. Antifungal susceptibility testing to predict appropriate initial antifungal therapy and outcome in non-*Aspergillus* invasive mold infections. Oral Presentation P322, 7th Trends in Medical Mycology (TIMM), Lisbon, Portugal, October 9-12, 2015
  84. Mullane KM; Adachi JA, Dubberke ER, **Alexander BD**, Broyde N, Sears PS. Outcomes of DEFLECT-1: a multicenter, blinded, randomized clinical trial of fidaxomicin vs. placebo for prophylaxis of *Clostridium difficile*-associated diarrhea in patients undergoing hematopoietic stem cell transplantation. Abstract, Bone Marrow Transplant (BMT) 2016 Tandem CIBMTR/ASBMT Meeting, Honolulu, Hawaii, February 18-22, 2016
  85. Lamoth, F, Damonti, L, **Alexander BD**. Epidemiology of invasive aspergillosis: a 4-year single center retrospective analysis. Abstract, 7<sup>th</sup> Advances Against Aspergillosis meeting Manchester, UK, March 3-5, 2016.
  86. Baker A, Maziarz E, Arif S, **Alexander BD**, Wolfe C. *Mycobacterium abscessus* infection in solid organ transplant recipients. Abstract. IDWeek2016, New Orleans, LA, October 29, 2016.
  87. **Alexander BD**, Schell WA, Jones AM, Hoekstra WJ, Schotzinger RJ, Garvey EP. CYP51 Inhibitors VT-1161 and VT-1129 show strong activity in vitro against *Candida krusei*. Abstract 1638. IDWeek2016, New Orleans, LA, October 28, 2016.
  88. Wolfe CR, Baker AW, Pael CB, Milano CA, Schroder JN, Daneshmand MA, **Alexander BD**, Maziarz, EK. *Mycobacterium abscessus* Infection in Patients with Ventricular Assist Devices. Abstract, International Society for Heart and Lung Transplantation, San Diego, CA, April 5-8 2017.
  89. Maziarz EK, Baker AW, Patel CB, Patel P, Milano CA, Schroder JN, Daneshmand MA, **Alexander BA**, Wolfe CR. Invasive *Mycobacterium abscessus* Infection in Heart Transplant Recipients. International Society for Heart and Lung Transplantation Annual Meeting. April 5-8, 2017. San Diego, CA.

90. Baker AW, Maziarz EK, Lewis SS, Stout JE, Anderson DJ, Smith PK, Schroder JN, Daneshmand MA, **Alexander BD**, Sexton DJ, Wolfe CR. Invasive *Mycobacterium abscessus* infection after cardiac surgery: epidemiology and clinical outcomes. Abstract 999 (selected for oral presentation), IDWeek Conference. October 4-8, 2017. San Diego, CA.
91. Smith B, Huslage K, **Alexander BD**, Messina J, Sexton DJ. An increase in invasive infections due to *Corynebacterium striatum* at an academic medical center. Abstract, IDWeek Conference. October 4-8, 2017. San Diego, CA.
92. Messina JA, Sung AD, Chao NJ, **Alexander BD**. The timing and epidemiology of *Enterococcus faecium* and *E. faecalis* bloodstream infections in patients with acute leukemia receiving chemotherapy. Abstract 1014. 59th Annual Meeting and Exposition, American Society of Hematology. December 9-12, 2017. Atlanta, GA.
93. Permpalung N, Thaniyavarn,T, Saullo J, Arif S, Miller R Reynolds J, **Alexander BD**. Rejection outcomes in lung transplant recipients post Respiratory Syncytial Virus infections. Abstract 1599. IDWeek Conference. October 3-7, 2018, San Francisco, CA.
94. Permpalung N, Thaniyavarn,T, Saullo J, Arif S, Miller R Reynolds J, **Alexander BD**. An optimal respiratory syncytial virus (RSV) treatment in lung transplant recipients: oral ribavirin, inhaled ribavirin or conservative approach. Abstract 1600. IDWeek Conference. October 3-7, 2018, San Francisco, CA.
95. Messina J, Hemmersbach Miller M, Sung A, **Alexander BD**, Chao N. Impact of enterococcal bloodstream infection on mortality in patients with acute myelogenous leukemia. Abstract 1017. IDWeek Conference. October 3-7, 2018, San Francisco, CA.
96. Cornely OA, Ostrosky-Zeichner L, Miller R, Spec A, Thompson G, Walsh TJ, Richardson R, Krause R, Pappas PG, Mullane K, Mors CG, Sanders JW, Weiss G, Witzke O, Vazquez J, Miceli MH, Patterson T, Hoenig M, **Alexander BD**, Angulo Gonzalez D. Favorable response to oral Ibrexafungerp (formerly SCY-078) in patients with refractory fungal diseases, interim analysis by pathogen from a phase 3 open-label study (FURI). Abstract L0010. 29<sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). April 13-16, 2019. Amsterdam, Netherlands.
97. Eichenberger E, Ruffin F, Jung SH, Lerebours R, Sharma-Kuinkel BK, **Alexander BD**, Thaden J, Fowler VG. Clinical characteristics and acute-phase cytokine response of solid-organ transplant recipients with bloodstream infections differs according to bacterial type and transplant status. Abstract 156, IDWeek Conference. October 2-6, 2019, Washington DC.
98. Steinbrink JM, Hua K, Myers R, Johnson MD, Seidelman J, Tsalik EL, **Alexander BD**, McClain MT. A host transcriptional signature for accurate diagnosis of candidemia in the hospital setting. Abstract 2885, IDWeek Conference. October 2-6, 2019, Washington DC.
99. **Alexander BD**, Kohler P, Pappas PG, Miller R, Johnson M, Vazquez J, Ostrosky-Zeichner L, Spec A, Richardson R, Bazaz R. Krause R, Prattes J, Zurl C, Thompson G, Walsh TJ, Sanders JW, Morse CG, Andes D, Lyon G, Marty F, Silverman E, Miceli MH, Patterson T, Hoenigl M, Azie N, Angulo D, Cornely O. Efficacy and safety of oral



- Ibrexafungerp in 41 patients with refractory fungal diseases, interim analysis of a phase 3 open-label study (FURI). Abstract 1248, IDWeek Conference. October 21-25, 2020. Virtual Meeting.
100. Marty FM, **Alexander BD**, Brissot E, Harber M, Maertens J., Papanicolaou GA, Silveira FP, Witzke O, Jingyang W, Fournier M. A phase 3 randomized study of maribavir versus investigator-assigned antiviral therapy for the treatment of refractory/resistant cytomegalovirus infection in hematopoietic cell or solid organ transplant recipients. Late Breaker Abstract LBA2, Oral Presentation at The Transplantation & Cellular Therapy Meetings. February 8-12, 2021. Virtual Meeting.
  101. Ostrosky-Zeichner L, Nguyen MH, Bubalo J, **Alexander BD**, Miceli MH, Papeas P, Jiang J, Song Y, Thompson GR. Multi-centre registry of patients receiving systemic mould-active triazoles for treatment or prophylaxis of invasive fungal infections. Abstract 1960. Oral Presentation at European Congress of Clinical Microbiology & Infectious Diseases. July 9-12, 2021. Virtual Meeting.
  102. Pappas PG, Cornely O, Koehler P, McCarty TP, **Alexander BD**, Miller R, Vazquez JA, Sanders JW, Morse C, Ostrosky-Aeichner L, Krause R, Jurgen P, Spec A, Rautemaa-Richardson R, Bazaz R, Walsh TJ, Marty FM, Gonzales-Bocco IH, Miceli M, Hoenigl M, Patterson TF, Azie N, Angulo DA. Oral ibrexafungerp outcomes by fungal disease in patients from an interim analysis of a phase 3 open-label study (FURI). Abstract 123, IDWeek Conference. September 29 – October 3, 2021. Virtual Meeting.
  103. Fournier M, **Alexander BD**, Brissot E, Harber M, Maertens J, Papanicolaou GA, Silveira FP, Witzke O, Jingyang W. A phase 3 randomized study of maribavir versus investigator-assigned antiviral therapy for the treatment of refractory/resistant Cytomegalovirus infection in transplant recipients. Poster 1334. 18<sup>th</sup> Asia Pacific Congress of Clinical Microbiology and Infection (APCCMI). November 11-13, 2021, Singapore.

## Select Presentations

1. Infectious Diseases Diagnostics Consortium cost savings analysis. Presented 5 December 1997, 4<sup>th</sup> Bi-annual Symposium of the Infectious Diseases Diagnostics Consortium, Concord, NC.
2. Mycoses in the transplanted – update of the mycology laboratory in the management of invasive fungal infections. Presented 10 May 2000, The 14<sup>th</sup> Congress of the International Society for Human and Animal Mycology, Buenos Aires, Argentina.
3. Old and new tools for diagnosis of fungal infection. Presented 15 May 2001, The Second Annual Joint meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Chicago, Illinois.
4. Role of new antifungals: from bench to bedside – Clinical utility of new antifungals in solid organ transplantation and ICUs. Presented 27 October 2001, The 39<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA.
5. New anti-CMV therapies in solid organ transplantation. Presented 29 September 2002, 42<sup>nd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA.
6. Fungal infections and transplantation: an update on shifting epidemiology and emerging risk factors. Presented 21 March 2003, 13<sup>th</sup> Annual Focus on Fungal Infections Meeting, Maui HI.
7. Invasive Mycoses following liver transplantation. Presented 11 April 2003, 21<sup>st</sup> Annual Meeting of the Japanese Liver Transplantation Society, Nagasaki, Japan.
8. New diagnostic assays for the detection of fungal infection after transplantation. Presented 27 May 2003, 15<sup>th</sup> Congress of the International Society for Human and Animal Mycology, San Antonio, TX.
9. Meet-the-Expert Session 131 - Newer anti-fungal agents for transplant and cancer patients. Presented 16 September 2003, 43<sup>rd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL.
10. Meet-the-Professor Session 24 - Transplant Infectious Diseases. Presented 11, 12 October 2003, 41<sup>st</sup> Annual Meeting of Infectious Disease Society of America, San Diego, CA.
11. Update on fungal diagnostics. Presented 5 March 2004, Carolinas Clinical Conference, Wilmington, NC.
12. Early therapy for aspergillosis. Presented 25 March 2004, 14<sup>th</sup> Annual Focus on Fungal Meeting, New Orleans, LA.
13. Success in antifungal therapy: breakthrough and emerging pathogens. Presented 30 September 2004, 42<sup>nd</sup> Annual Meeting of the Infectious Diseases Society of America, Boston, MA.
14. Role of echinocandins in antifungal therapy. Presented 30 October 2004, 44<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC.
15. ABLC renal safety: analysis of the CLEAR data. Presented 20 March 2005, 31<sup>st</sup> Annual Meeting of the European Group for Blood and Marrow Transplantation, Prague, Czeck Republic.

16. Considerations for prophylaxis therapy for invasive fungal infections. Presented 18 December 2005, 45<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC.
17. Fungal Diagnostics: Are we there yet? Presented 5 April 2006, 26<sup>th</sup> Annual Meeting International Society for Heart and Lung Transplantation, Madrid Spain.
18. Antifungal susceptibility testing needs: the clinician's perspective. Presented September 2006, 46<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA.
19. Meet-the-Expert Session – Fungal diagnosis: new directions. Presented 19 September 2007, 47<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago IL.
20. Infectious complications after transplant. Presented 19 September 2008, Duke Department of Surgery and Section of Abdominal Transplant Surgery sponsored symposium on the Current Status of Renal Transplantation, Durham, NC.
21. Diagnosis and management of invasive aspergillosis. Presented 25 October 2008, 48<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy/46<sup>th</sup> Infectious Diseases Society of America Joint Meeting, Washington, DC.
22. Infectious complications of solid organ transplantation. Presented 21 January 2009, Icelandic Medical Association Annual Meeting, Reykjavik, Iceland.
23. Advances in fungal diagnostics. Presented 21 March 2009, Society for Healthcare Epidemiology of America Annual Meeting, San Diego, CA.
24. Optimal approaches for anti-fungal susceptibility of filamentous fungi. Presented 13 September 2009, 49<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA.
25. Infections in solid organ transplant recipients. Presented 11 December 2009, Brooke Army Medical Center, Fort Sam Houston, TX.
26. Current strategies for diagnosing aspergillosis and mucormycosis. 7 April 2010, Annual Mycoses Study Group Meeting, Philadelphia, PA.
27. Transplant transmitted infections: avoiding the poison apple. 23 April 2010, 18<sup>th</sup> Annual United Network for Organ Sharing Transplant Management Forum. Orlando, FL.
28. Meet-the-Expert Session - Clinical and laboratory challenges in pulmonary mycoses. Presented 14 September 2010, 50<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA.
29. Epidemiology and prevention of early infections in lung transplant patients: what's new? Not fungal infections. Presented 14 September 2010, 50<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA.
30. Update on fungal infections 2011--case studies of mucormycosis. Presented 23 March 2011. Medicine Grand Rounds, Robert Wood Johnson Medical School, New Brunswick, NJ.
31. Infections in solid organ transplant recipients. Presented 10 May 2011, 48<sup>th</sup> Annual William J. Holloway Infectious Disease Symposium, Newark, DE
32. Transplant associated infections. Presented 11 May 2011, Annual Infectious Diseases Society of New Jersey Symposium, Iselin, NJ

33. Interactive cases in mycology: Pulmonary nodules in a patient with leukemia. Presented 18 September 2011, 51<sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago IL.
34. Infections in solid organ transplant recipients. Presented 31 March 2012, Featured presentation, Annual South Carolina Infectious Diseases Society Meeting, Charleston, SC.
35. Invasive mold infections in the Duke renal transplant population case review, Transplant Academia Conference, Duke University, Durham, NC, 14 August 2012.
36. Transplantation & the ID physician: management strategies for the 21<sup>st</sup> century. Laboratory monitoring for fungi in transplantation: advantages and limitations. Presented 9 September 2012, 52<sup>nd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA.
37. Meet-the-Expert Session: Infectious complications of lung transplantation. Presented 21 May 2013, American Transplant Congress, Seattle, Washington.
38. Invasive fungal infections after solid organ transplantation. Presented 11 September 2013, 52<sup>nd</sup> Mycosis Study Group Meeting / Interscience Conference on Antimicrobial Agents and Chemotherapy. Denver CO.
39. Vincent T. Andriole Board Review Course: Infections in transplant patients. Presented 1 October 2013, 51<sup>st</sup> Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA.
40. Use of New Antibiotics: FDA Indications and Beyond. Presented 29 October 16, IDWeek2016, New Orleans, LA.
41. The clinical mycology laboratory: guiding therapeutic choices. Presented 30 March 2017, Keynote Speaker, 31<sup>st</sup> Annual Yash P. Kataria Internal Medicine Research Day, East Carolina University, Greenville, NC.
42. Non-Cultural Methods for Diagnosis & Prevention of Invasive Fungal Infections: Are We There Yet? Presented 5 April 2017, 37<sup>th</sup> Annual Meeting and Scientific Sessions of the International Society of Heart and Lung Transplantation, San Diego, CA.
43. Advances in fungal diagnostics: guiding therapeutic choices. Presented 23 May 17, Department of Medicine Grand Rounds, Northwestern University Feinberg School of Medicine, Chicago IL.
44. Transplant/Immunocompromised Host Infectious Diseases Service: Providing Concierge Level Care. Presented 21 October 2017, Duke Infectious Diseases 40<sup>th</sup> Anniversary Symposium, Duke University, Durham, NC.
45. Pre-meeting Fellow's Day/Workshop: ID Career Path Breakout Discussions "Transplant/Oncology ID". Presented 4 October 2017, IDWeek2017, San Diego, CA.
46. Managing and mitigating transplant infections: bread and butter transplant ID – the antifungal landscape. Presented 2 June 2018, American Transplant Congress, Seattle, Washington.
47. Pre-meeting Fellow's Day/Workshop: ID Career Path Breakout Discussions "Transplant/Oncology ID". Presented 3 October 2018, IDWeek2018, San Francisco, CA.

48. Advances in fungal diagnostics: guiding therapeutic choices. Presented 24 October 2018, University of Texas Southwestern Infectious Diseases Grand Rounds, Dallas TX.
49. Advances in fungal diagnostics: guiding therapeutic choices. Presented 13 November 2018, University of Minnesota Infectious Diseases Grand Rounds, Minneapolis, MN.
50. Advances in fungal diagnostics: guiding therapeutic choices. Presented 5 April 2019, 93<sup>rd</sup> Annual Meeting of the Japanese Association for Infectious Diseases, Nagoya, Japan.
51. Top 10 papers in transplant infectious diseases. Presented 3 June 2019, American Transplant Congress, Boston MA.
52. Diagnostic updates: clinical mycology - fungal biomarkers. Presented 5 October 2019, IDWeek2019, Washington DC.
53. Expert VIP Meet-UP: Preventing fungal infections after transplantation. Presented 8 June 2021, American Transplant Congress. (Virtual)
54. Updates in Transplant ID; updates from IDSA. Presented 12 June 2021, Texas Infectious Diseases Society Annual Meeting. (Virtual)
55. New educational tools to teach/learn infectious diseases and clinical microbiology. Presented 11 July 2021, European Congress of Clinical Microbiology & Infectious Diseases. (Virtual)

### **Consultant Appointments**

- 2006-2022     Clinical and Laboratory Standards Institute  
                   Subcommittee on Antifungal Susceptibility Tests  
                   2008 Lead, M44-A2 Revision Working Group  
                   2012, Chair-Elect  
                   **2014-2017, Chair**  
                   2017, Lead, M60 Revision Working Group  
                   2018-2020, Past-Chair  
                   2019-2022, Epidemiologic Cutoff Values Working Group
- 2007-2022     Food and Drug Administration (FDA), Center for Drug Evaluation and Research  
                   2007-2016, Consultant, Antimicrobial Drugs Advisory Committee  
                   2018-present, Member, Microbiology Devices Panel

### **Professional awards and special recognitions**

- 1993   North Carolina Chapter of the American College of Physicians Award  
 1995   Duke University Annual Resident Research Award  
 1998   American Society for Microbiology Infectious Diseases Fellow Travel Grant  
 2000   Merck & Co. Wayne Ebrite Scholar  
 2008   Elected Fellow, Infectious Diseases Society of America (FIDSA)  
 2015   Leonard Palumbo, Jr., MD, Duke University Faculty Achievement Award  
 2017   CLSI Excellence in Consensus Management Award  
 2020   Medical Mycological Society of the Americas Billy H. Cooper Award in Medical Mycology ([https://www.mycologicalsociety.org/billy\\_h\\_cooper\\_award](https://www.mycologicalsociety.org/billy_h_cooper_award))

## **Organizations and participation**

- 1989-2022 American Medical Association  
1992-93 Vice-chair, Medical Student Section National Governing Council
- 1989-2019 North Carolina Medical Society  
1996-97 Chair, Resident Physician Section  
1991-93 Infectious Diseases and AIDS Committee  
1991-92 Vice-chair, Medical Student Section
- 1992-1993 Medical Student Representative to the National Board of Medical Examiners
- 1996-2022 Infectious Diseases Society of America (IDSA)  
2004-11 Annual Meeting Program Committee  
2005 Lead Reviewer, Fungal Abstracts  
Distinguished Poster Faculty  
Moderator: Impact of novel immunosuppressive regimens on infections in transplant recipients  
Moderator: Clinical issues in the practice of ID  
2006 Lead Reviewer, Fungal Abstracts  
Moderator: Antifungal formulary 2006  
Moderator: Challenges in CMV infection  
2007 Lead Reviewer, Fungal Abstracts  
Moderator: Fungal disease in immunocompromised cancer patients: new strategies in the era of prophylaxis  
Moderator: Viral infections: new challenges in transplantation  
2008 Reviewer, Diagnostic Abstracts  
Moderator: Invasive aspergillosis: new diagnostic platforms & targets  
2009 Lead Reviewer, Diagnostic Abstracts  
Moderator: Nucleic acid testing for screening organ donors  
Moderator: The new age of TB diagnostics  
Moderator: AST/IDSA guidelines update  
Moderator: Oral Abstract Session: Mycology and transplant ID  
2010-11 Chair-Elect, Annual Meeting Program Committee  
2010 Lead Reviewer, Diagnostic Abstracts  
Reviewer, Late-Breaker Abstracts  
Moderator: New tools for diagnosing aspergillosis  
Moderator: Joseph E. Smadel Lecture  
Moderator: John F. Enders Lecture  
2011-12 Chair, Annual Meeting Program Committee  
2011 Lead Reviewer, Diagnostic Abstracts  
Reviewer, Late-Breaker Abstracts  
2007-08 Organizer/Co-Chair, Transplantation ID & Compromised Hosts Working Group  
2009 Chair, Transplantation ID & Compromised Hosts Working Group  
2010 Education Committee

2013-16 IDSA ID Training Program Directors' Committee  
 2013-16 IDSA Board of Directors  
 2015-16 IDSA ID Recruitment Task Force  
 2018-19 IDSA Vice-President  
 2018-19 IDSA Society Awards Committee Member  
 2018-19 IDSA Conflict of Interest Ethics Committee  
 2018-19 IDSA Strategic Planning Task Force  
 2019-20 IDSA President-Elect  
 2019-20 Chair, IDSA Society Awards Committee  
**2020-21 IDSA President**  
 2021-22 Immediate Past President  
 2021-22 Board Liaison to Standards & Practice Guidelines Committee  
 1997-2015 American College of Physicians  
 1998-2021 American Society for Microbiology  
 2000-2022 American Society of Transplantation  
     2000-08 Infectious Disease Community of Practice Executive Committee  
     2004-07 Grants and Awards Committee  
     Annual American Transplant Congress  
         2003 Moderator: Infectious diseases and immunization  
         2004 Abstract Review Committee  
         2009 Abstract Review Committee  
 2001-2021 The Transplantation Society  
     World Transplant Congress  
         2006 Abstract Review Committee  
         2006 Moderator: Fungal and emerging infections  
 2003-2006 Academic Advisory Board Member – Pfizer Fellowships in Infectious Diseases  
 2002-2022 Ad Hoc Reviewer: *American Journal of Transplantation, Transplant Infectious Diseases, Mycopathologica, Clinical Infectious Diseases, Journal of Infectious Diseases, Transplantation, Liver Transplantation, Journal of Antimicrobial Chemotherapy, Medical Mycology, Biology of Blood and Marrow Transplantation, New England Journal of Medicine*  
 2006-2010 Editorial Board, *Antimicrobial Agents and Chemotherapy*  
 2009-2012 Editorial Board, *Virulence*  
 2011-2016 Associate Editor, *Clinical Infectious Diseases*  
 2016-2020 Associate Deputy Editor, *Clinical Infectious Diseases*  
 2004-2022 International Society for Heart & Lung Transplantation (ISHLT)  
     Annual ISHLT Meeting  
         2006 Abstract Review Committee  
         2007 Program Committee and Abstract Review Committee  
         2008 Abstract Review Committee  
 2006-2022 Mycoses Study Group (MSG)  
     2007-2014 Education Committee

Representative to FDA/EMA hearing for galactomannan biomarker qualification, Washington, DC, July, 2008

2018-22 MSG Board of Directors

2013-present International Pediatric Fungal Network, Advisory Board Member

2020 American Society of Association Executives, Exceptional Boards - Strengthening the Governance Team Workshop. Attendee January 27-28,2020, Naples FL.

2020-present The COVID Collaborative (<https://www.covidcollaborative.us/the-collaborative>)

### **Areas of research interest**

Clinical research related to infectious complications of solid organ and hematopoietic stem cell transplantation, with a particular interest in the prevention and rapid diagnosis of fungal infections.

### **GIFTS, GRANTS, AND CONTRACTS**

#### **PAST EXTERNAL SUPPORT**

**Burroughs Wellcome Community Service Grant** 1990

PI: Alexander

*Greenville Community Shelter Medical Clinic Building Fund*

**United Way Venture Grant** 1992

PI: Alexander

*Greenville Community Shelter Medical Clinic Building Fund*

**Kate B. Reynold's Health Care Trust Fund Grant** 1993

PI: Alexander

*Greenville Community Shelter Medical Clinic Building Fund*

**T32 AI07392** 1997-1999

NIH NIAID (PI: Hamilton / Trainee: Alexander)

Interdisciplinary Research Training Program in AIDS Grant

*Evaluation of diagnostic tests for tuberculosis*

**Investigator Initiated Research Grant** 2001-2005

Enzon Pharmaceuticals (PI: Alexander)

*Noncomparative evaluation of the safety and tolerability of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation.*

**K12 RR17630-02** 2002-2005

NIH (PI: Zaas / Role on Grant: Mentor)

*Innate Immunity to Aspergillus fumigatus*



<b>T32 CA093245-03</b>	2004–2005
NIH (PI: Hanson / Role on Grant: Mentor)	
<i>Molecular diagnostic testing for CMV surveillance after allogeneic HSCT</i>	
<b>K23 AI52222</b>	2002-2007
NIH NIAID (PI: Alexander)	
<i>Prevention and diagnosis of fungal infections in transplant populations</i>	
<b>Society of Infectious Diseases Pharmacists (SIDP) Grant</b>	2003-2006
SIDP (PI: Dodds Ashley / Role on Grant: Co-Investigator & Mentor)	
<i>Characterization of aerosolized ABLC lung distribution</i>	
<b>K12 RR17630-02</b>	2005–2008
NIH/NIAID(PI: Hanson/ Role on Grant: Mentor)	
<i>Quantitative viral load testing and measures of T-cell immune reconstitution for CMV</i>	
<b>Investigator Initiated Research Grant</b>	2006-2009
Enzon Pharmaceuticals (PI: Alexander)	
<i>Susceptibility to Invasive Aspergillosis: Role of Mannose Binding Lectin</i>	
<b>K08 AI065837-01</b>	2005-2009
NIH/NIAID (PI: Zaas / Role on Grant: Co-Investigator)	
<i>Genetic determinants of Aspergillus fumigatus susceptibility</i>	
<b>Investigator Initiated Research Grant</b>	2007-2009
Astellas Pharma US, Inc (PI: Alexander)	
<i>Aerosolized micafungin feasibility study</i>	
<b>Industry Sponsored Clinical Trial</b>	2008-2009
Myconostica (Site PI: Alexander)	
<i>FXGTM: RESP test for detection of Aspergillus and Pneumocystis in clinical specimens</i>	
<b>Industry Sponsored Clinical Trial</b>	2008-2010
Pfizer, Inc. (Site PI: Alexander)	
<i>Anidulafungin &amp; voriconazole in combination vs. voriconazole alone for invasive aspergillosis</i>	
<b>U01-AI066590</b>	2005-2010
NIH/NIAID (PI: Mitchell / Role on Grant: Co-Investigator)	
<i>Microfluidic PCR platform to detect microbial (Candida, Mycoplasma) DNA in clinical samples</i>	
<b>Investigator Initiated Research Grant</b>	2008-2010

Astellas Pharma US, Inc (PI: Alexander)  
*Aerosolized liposomal amphotericin B (LAMB) cascade impaction study*

**1KL2 RR024127-03** 2008-2011  
NIH/NIAID (PI: Pfeiffer / Role on Grant: Mentor)  
*Diagnosing candidemia using proteomics, a novel technique*

**Investigator Initiated Research Grant** 2007-2012  
Pfizer, Inc. (PI: Alexander)  
*Randomized comparison of  $\beta$ -D-glucan surveillance with preemptive anidulafungin*

**T32 AI052080-03** 2011-2012  
NIH (PI: Horan / Role on Grant: Mentor)  
*Molecular mycology and pathogenesis of *Paecilomyces*, an emerging fungal pathogen*

**T32 AI052080-03** 2012-2013  
NIH (PI: Catania / Role on Grant: Mentor)  
*RNA-based amplification assay for detection of *Candida* bloodstream infection*

**K24 AI072522** 2007-2013  
NIH/NIAID (PI: Alexander)  
*Preventing and diagnosing fungal disease in transplantation*

**Investigator Initiated Research Grant** 2011-2013  
Astellas Pharma US, Inc (PI: Alexander)  
*Echinocandin resistance in *Candida glabrata**

**Investigator Initiated Research Grant** 2012-2013  
Astellas Pharma US, Inc (Role on Grant: Site Investigator)  
*Open label study of isavuconazole in the treatment of aspergillosis or invasive fungal disease cause by rare molds, yeasts, or dimorphic fungi*

**Investigator Initiated Research Grant** 2007-2014  
Astellas Pharma US, Inc (PI: Alexander)  
*Transplant Infections Network: Multicenter study for surveillance of invasive fungal infections in US transplant populations and the collection of fungal isolates and serum samples for banking/future studies.*

**DMID-07-13** 2007-2015  
NIH/NIAID (PI: Wingard / Role on Grant: Co-PI)  
*Aspergillus Technology Consortium*

Multicenter consortium to establish a repository of clinical samples from patients at high risk for and with IA, and to conduct laboratory studies to evaluate the performance of new diagnostic tests for IA.

**Industry Sponsored Clinical Trial** 2010-2015

Charles River Laboratories (Role on Study: PI)

Multicenter study to establish the non-inferiority of the sensitivity of the Charles River Laboratories beta glucan (BG) test compared with the sensitivity of the Fungitell BG test for the diagnosis of invasive candidiasis and invasive aspergillosis; data generated to be used to support FDA submission.

**Industry Sponsored Clinical Trial** 2012-2015

Optimer Pharma (Role on Study: Site Investigator)

DEFLECT-1: Phase 3b multi-center, double-blind, randomized, placebo controlled study to demonstrate the safety and efficacy of fidaxomicin for prophylaxis against *Clostridium difficile*-associated diarrhea in adults undergoing hematopoietic stem cell transplantation

**Industry Sponsored Clinical Trial** 2013-2015

ViroPharma (Role on Study: Site Investigator)

Phase 2, randomized study to assess the safety & anti-cytomegalovirus activity of maribavir for treatment of CMV infections resistant or refractory to treatment with ganciclovir/valganciclovir or foscarnet in transplant recipients

**Research Grant** 2012-2016

Mycoses Study Group (Role on Grant: Site Investigator)

*A Case Registry of Patients with Phaeoohyphomycosis*

Multicenter study to establish a case registry of patients with phaeoohyphomycosis in order to describe epidemiology, treatment practices, and patient outcomes.

**Investigator Initiated Research Grant** 2014-2016

Viamet (PI: Alexander)

*Activity of VT1161 and VT1598 against clinical isolates*

**Investigator Initiated Research Grant** 2014-2016

Scynexis (PI: Alexander)

*Activity of SCY-078 (MK-3118), a new oral glucan synthase inhibitor, against clinical isolates*

**Duke University School of Medicine** 2016-2018

PI: Quinones; Role on Grant: Co-PI

*Sequencing and Genomic Technologies Shared Resource Award*

Whole genome sequencing on *Burkholderia* clinical isolates to investigate mechanisms of virulence and resistance.

**R21AI132978-01** 2017–2019

NIH/NIAID (PI: McClain; Role on Grant: Investigator)

Host-derived biomarker signatures to differentiate acute viral, bacterial, and fungal infection.

**Industry Sponsored Research (Astellas)** 2017–2020

Astellas (Role on Grant: Site PI)

Observational disease registry of patients treated with systemic mold-active triazoles (MAT Registry).

**Industry Sponsored Research Grant (Astellas)** 2012-2021

WHISCON (PI: Schneeweiss; Role on Grant: Site Investigator)

*Multicenter cohort study of the short and long-term safety of parenteral antifungal agents*

Multicenter observational cohort study to establish the risks of short and long-term outcomes in users of parenteral micafungin and in users of other parenteral antifungal agents from 2005 - 2010.

**Industry Sponsored Clinical Trial (Shire)** 02/2017–03/2021

Shire (Role on Grant: Site PI)

SHP620-303 - Phase 3, multicenter, randomized, open-label, active-controlled study to assess the efficacy and safety of maribavir treatment compared to investigator-assigned treatment in transplant recipients with CMV infections refractory to SOC.

### **PRESENT EXTERNAL SUPPORT**

**T32 AI100851-01** 07/2013-06/2023

NIH/NIAID (Role on Grant: PI/Program Director)

*Transplant Infectious Diseases Interdisciplinary Research Training Grant (TIDIRTG)*

Combined clinical care, research and laboratory medicine training program focused on the treatment of transplant/immunocompromised host.

**Industry Sponsored Clinical Trial (Scynexis)** 12/2016-04/2022

Scynexis (Role on Grant: Study Protocol PI)

*301 (FURI) Study*: Multinational, open label study to evaluate the efficacy and safety of SCY-078 in patients with fungal disease that are refractory to or intolerant of standard antifungal treatment.

**Industry Sponsored Research (Astellas)** 03/2017–12/2022

Astellas (Role on Grant: Site PI)

Non-interventional registry study of systemic antifungal therapy in adult subjects with invasive mucormycosis or invasive aspergillosis caused by a non-fumigatus species (PMC Registry).

**Industry Sponsored Research (Leadiant)**

07/2018-06/2022

Leadiant (Role on Grant: Study Protocol PI)

Efficacy and safety of aerosolized amphotericin B lipid complex in the lung transplant population:

**R42AI115866**

07/2017-06/2021

NIH/NIAID (PI: Marr; Role on Grant: Investigator)

Optimize laboratory production of the AspUTest device; to determine performance characteristics of AspUTest as an aid to diagnose invasive aspergillosis using samples obtained from patients with hematological malignancies; and to validate and test the performance of AspUTest in the clinical microbiology laboratory.

**Clinical activity - type of practice and estimate of time commitment**

I serve as Director of the Transplant ID Service and provide acute inpatient consultative support to both solid organ and hematopoietic stem cell transplant (HSCT) services three months per year. I have an outpatient clinic one half day per week dedicated to transplant ID outpatient consultation and follow-up.

**Participation in academic / administrative activities of Duke University and Medical Center**

1995-1997 Institutional Committee for Graduate Medical Education

1999-present Director, Transplant Infectious Diseases Service

*Administrative responsibilities include scheduling Transplant ID faculty, organizing Transplant ID conferences and research, developing and monitoring antimicrobial protocols for the transplant services, bringing in clinical research protocols (including compassionate use protocols) to have available for Duke transplant patients, and being available for telephone consults from the transplant clinicians.*

1999-present Head, Mycology Section, Clinical Microbiology Laboratory

*Administrative responsibilities include serving as microbiology faculty, rounding and teaching in the Clinical Microbiology Laboratory, attending weekly clinical microbiology faculty meetings, supervising medical technologists, developing and implementing mycology section annual goals, and bringing new assays into the laboratory for clinical care.*

1999-present Faculty, DUMC Medical Microbiology Fellowship Program

2011-2019 Program Director, DUMC Medical Microbiology Fellowship Program

1999-2011 Antibiotic Evaluation Team

2002-present Faculty (Mentor), NIH 1K12RR17630-02 Duke University Mentored Clinical Research Scholar Program

2002-present Faculty Member, Duke Clinical Research Institute

2003-2005 Infectious Diseases Division Nomination Committee

2003-present Faculty, NIH T32 Molecular Mycology and Pathogenesis Training Program,  
Department of Molecular Genetics and Microbiology, DUMC

2005-present Duke University Mycology Research Unit & Center for Microbial Pathogenesis

2008 Duke University Department of Radiology 5-Year Review Committee

2008 Search Committee, Chief of ID and International Health, Duke University  
Author of white paper providing *Comprehensive Review of Division of  
Infectious Diseases and International Health*

2009 Duke University Department of Medicine Strategic Hiring Committee

2009-2015 Faculty, Annual Southeastern Fellows Research Skills Retreat

2010 Infectious Diseases Division Medical Advisory Board for Site Based Research

2010-2011 Search Committee, Chief of ID and International Health, Duke University

2011-2017 Search Committee, Medical Director Clinical Microbiology Laboratory

2013-present Principal Investigator, NIH T32 Transplant Infectious Diseases Interdisciplinary  
Research Training Grant, DUMC

2013-present Transplant Co-Management Leader

2013-present Transplant Strategy & Executive Oversight Committee (SEOC)

2013-present Transplant Quality & Compliance Committee (QCC)

2016 Search Committee, Chief Pediatric Infectious Diseases Division

2017-present Transplant Center Steering Committee

2017-present Transplant Center Education Committee

2018-present Department of Medicine Appointments, Promotion and Tenure Committee

2018-2019 Search Committee, Clinical Microbiology Laboratory Faculty Member